EX-10.1





 Exhibit 10.1 

EXECUTION VERSION 
 CERTAIN INFORMATION
IDENTIFIED BY BRACKETED ASTERISKS ([* * *]) HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

SECURITIES PURCHASE AGREEMENT 

This Securities Purchase Agreement (this “Agreement”) is dated as of July 6, 2020, by and among Unum Therapeutics Inc., a
Delaware corporation (the “Company”), and each purchaser identified on Annex A hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”).

 RECITALS 
 A. The Company
and each Purchaser is executing and delivering this Agreement in reliance upon the exemption from securities registration afforded by Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and Rule
506 of Regulation D (“Regulation D”) as promulgated by the United States Securities and Exchange Commission (the “Commission”) under the Securities Act. 

B. Each Purchaser, severally and not jointly, wishes to purchase, and the Company wishes to issue and sell, upon the terms and conditions
stated in this Agreement, an aggregate of 118,637 shares (the “Securities”) of Series A Non-Voting Convertible Preferred Stock, par value $0.001 per share (the “Series A Preferred
Stock”) of the Company, having the designation, preferences, conversion or other rights, voting powers, restrictions, limitations as to dividends, qualifications and terms and conditions as specified in the Certificate of Designations,
substantially in the form attached hereto as Exhibit A (the “Certificate of Designations”), which will be convertible into shares (the “Conversion Shares”) of the Company’s common stock, par value $0.001
per share (“Common Stock”), in accordance with the terms set forth in the Certificate of Designations. 
 C. Pursuant to
the terms and conditions of the Certificate of Designations, the conversion of the Series A Preferred Stock shall be subject to receipt of the Requisite Stockholder Approval (as defined therein). 

D. The Company has engaged Jefferies LLC as its exclusive placement agent (the “Placement Agent”) for the offering of the
Securities on a “best efforts” basis. 
 E. Prior to the Closing: (i) the parties hereto shall execute and deliver a
Registration Rights Agreement, substantially in the form attached hereto as Exhibit B (the “Registration Rights Agreement”), pursuant to which, among other things, the Company will agree to provide certain registration rights
with respect to the Conversion Shares under the Securities Act and the rules and regulations promulgated thereunder and applicable state securities laws and (ii) the Company shall file with the Delaware Secretary of State the Certificate of
Designations, duly executed by an officer of the Company. 
 F. Concurrent with the execution and delivery of this Agreement, the Company is
entering into an Agreement and Plan of Merger by and among the Company, Utah Merger Sub 1 LLC (the “First Merger Sub”), Utah Merger Sub 2 LLC (the “Second Merger Sub”), and Kiq, LLC (“Kiq”), in
substantially the form attached hereto as Exhibit H attached hereto (the “Merger Agreement”), the Company and Kiq intend to effect a merger of First Merger Sub with and into the Company (the “First Merger”)
in accordance with this Merger Agreement. Upon consummation of the First Merger, the First Merger Sub will cease to exist and Kiq will become a wholly owned subsidiary of the Company. Immediately following the First Merger and as part of the same
overall transaction as the First Merger, Kiq will merge with and into Second Merger Sub (the “Second Merger” and, together with the First Merger, the “Merger”), with Second Merger Sub being the surviving entity of
the Second Merger. 
 NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable
consideration, the receipt and adequacy of which are hereby acknowledged, the Company and the Purchasers hereby agree as follows: 












 ARTICLE I. 

DEFINITIONS 
 1.1
Definitions. In addition to the terms defined elsewhere in this Agreement, for all purposes of this Agreement, the following terms shall have the meanings indicated in this Section 1.1: 

“Acquiring Person” has the meaning set forth in Section 4.5. 

“Action” means any action, suit, inquiry, notice of violation, proceeding (including any partial proceeding such as a
deposition) or investigation pending or, to the Company’s Knowledge, threatened in writing against the Company, any subsidiary or any of their respective properties or any officer, director or employee of the Company or any subsidiary acting in
his or her capacity as an officer, director or employee before or by any U.S. federal, state, county, local or non-U.S. court, arbitrator, governmental or administrative agency, regulatory authority, stock
market, stock exchange or trading facility. 
 “Affiliate” means, with respect to any Person, any other Person that,
directly or indirectly through one or more intermediaries, Controls, is controlled by or is under common control with such Person, as such terms are used in and construed under Rule 405 under the Securities Act. With respect to a Purchaser, any
investment fund or managed account that is managed on a discretionary basis by the same investment manager as such Purchaser will be deemed to be an Affiliate of such Purchaser. 

“Agreement” has the meaning set forth in the Preamble. 

“Board of Directors” means the board of directors of the Company. 

“Business Day” means any day except Saturday, Sunday, any day which is a federal legal holiday in the United States or any
day on which banking institutions in the State of New York are authorized or required by law or other governmental action to close. 

“Certificate of Designations” has the meaning set forth in the Recitals. 

“Closing” means the closing of the purchase and sale of the Securities pursuant to this Agreement. 

“Closing Date” means the Trading Day when all of the Transaction Documents have been executed and delivered by the applicable
parties thereto, and all of the conditions set forth in Sections 2.1, 2.2, 5.1 and 5.2 hereof are satisfied or waived, as the case may be, or such other date as the parties may agree. 

“Commission” has the meaning set forth in the Recitals. 

“Company” has the meaning set forth in the Preamble. 

“Company Counsel” means Goodwin Procter LLP, with offices at 100 Northern Ave, Boston, MA 02210. 

“Company Deliverables” has the meaning set forth in Section 2.2(a). 

“Company’s Knowledge” means with respect to any statement made to the Company’s Knowledge, that the statement is
based upon the actual knowledge of the executive officers or directors of the Company having responsibility for the matter or matters that are the subject of the statement. With respect to any matters relating to Intellectual Property, such
awareness or reasonable expectation to have knowledge does not require any such individual to conduct or have conducted or obtain or have obtained any freedom to operate opinions of counsel or any Intellectual Property rights clearance searches.


  
 2 













 “Contract” means, with respect to any Person, any written agreement,
contract, subcontract, lease (whether for real or personal property), mortgage, license, or other legally binding commitment or undertaking of any nature to which such Person is a party or by which such Person or any of its assets are bound or
affected under applicable Law. 
 “Control” (including the terms “controlling”, “controlled by” or
“under common control with”) means the possession, direct or indirect, of the power to direct or cause the direction of the management and policies of a Person, whether through the ownership of voting securities, by contract or otherwise.

 “Effect” means any effect, change, event, circumstance or development. 

“Effective Date” means the date on which the initial Registration Statement required by Section 2(a) of the Registration
Rights Agreement is first declared effective by the Commission. 
 “Employee Plan” means any Employee Plan that the Company
or any of its Subsidiaries (i) sponsors, maintains, administers, or contributes to, or (ii) provides benefits under or through, or (iii) has any obligation to contribute to or provide benefits under or through, or (iv) with
respect to which have any liability, or (v) utilizes to provide benefits to or otherwise cover any current or former employee, officer, director or other service provider of the Company or any of its Subsidiaries (or their spouses, dependents,
or beneficiaries). 
 “Encumbrance” means any lien, pledge, hypothecation, charge, mortgage, security interest, lease,
exclusive license, option, easement, reservation, servitude, adverse title, claim, infringement, interference, option, right of first refusal, preemptive right, community property interest or restriction or encumbrance of any nature (including any
restriction on the voting of any security, any restriction on the transfer of any security or other asset, any restriction on the receipt of any income derived from any asset, any restriction on the use of any asset and any restriction on the
possession, exercise or transfer of any other attribute of ownership of any asset). 
 “Environmental Laws” has the meaning
set forth in Section 3.1(cc). 
 “Exchange Act” means the Securities Exchange Act of 1934, as
amended, or any successor statute, and the rules and regulations promulgated thereunder. 
 “Governmental Authority” means
any: (a) nation, state, commonwealth, province, territory, county, municipality, district or other jurisdiction of any nature, (b) federal, state, local, municipal, foreign, supra-national or other government, (c) governmental or
quasi-governmental authority of any nature (including any governmental division, department, agency, commission, bureau, instrumentality, official, ministry, fund, foundation, center, organization, unit, body or entity and any court or other
tribunal, and for the avoidance of doubt, any taxing authority) or (d) self-regulatory organization (including Nasdaq). 

“Intellectual Property Rights” has the meaning set forth in Section 3.1(n). 

“Irrevocable Transfer Agent Instructions” means, with respect to the Company, the Irrevocable Transfer Agent Instructions, in
substantially the form of Exhibit D, executed by the Company and delivered to and acknowledged in writing by the Transfer Agent. 

  
 3 













 “Law” means any federal, state, national, supra-national, foreign, local or
municipal or other law, statute, constitution, principle of common law, resolution, ordinance, code, edict, decree, rule, regulation, ruling or requirement issued, enacted, adopted, promulgated, implemented or otherwise put into effect by or under
the authority of any Governmental Authority (including under the authority of Nasdaq or the Financial Industry Regulatory Authority). 

“Material Adverse Change” has the meaning set forth in Section 3.1(j). 

“Material Adverse Effect” means any Effect, individually or together with any other Effect, that has had, has, or would
reasonably be expected to have a material adverse effect on the business, financial condition, assets, liabilities or results of operations of the Company or its subsidiaries, taken as a whole; provided, however, that Effects arising
or resulting from the following shall not be taken into account in determining whether there has been a Material Adverse Effect: (a) the announcement or disclosure of the sale of the Securities or other transactions contemplated by this
Agreement, (b) the taking of any action, or the failure to take any action, by the Company that is required to comply with the terms of this Agreement, (c) any natural disaster or epidemics, pandemics or other force majeure events, or any act
or threat of terrorism or war, any armed hostilities or terrorist activities (including any escalation or general worsening of any of the foregoing) anywhere in the world or any governmental or other response or reaction to any of the foregoing,
(d) any change in GAAP or applicable Law or the interpretation thereof, (e) general economic or political conditions or conditions generally affecting the industries in which the Company and its subsidiaries operate or (f) any change
in the cash position of the Company and its subsidiaries which results from operations in the ordinary course of business; except in each case with respect to clauses (c), (d) and (e), to the extent disproportionately affecting the Company and its
subsidiaries, taken as a whole, relative to other similarly situated companies in the industries in which the Company and its subsidiaries operate. 

“Nasdaq” means The Nasdaq Stock Market. 

“New York Courts” means the state and federal courts sitting in the City of New York, Borough of Manhattan. 

“Outside Date” means the thirtieth day following the date of this Agreement. 

“Person” means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture,
limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind. 

“Placement Agent” has the meaning set forth in the Recitals. 

“Press Release” has the meaning set forth in Section 4.4. 

“Principal Trading Market” means the Trading Market on which the Common Stock is primarily listed on and quoted for trading,
which, as of the date of this Agreement and the Closing Date, shall be the Nasdaq Global Select Market. 
 “Proceeding”
means an action, claim, suit, investigation or proceeding (including, without limitation, an investigation or partial proceeding, such as a deposition), whether commenced or threatened. 

“Purchase Price” has the meaning set forth in Section 2.1. 

“Purchaser” or “Purchasers” has the meaning set forth in the Recitals. 

“Purchaser Deliverables” has the meaning set forth in Section 2.2(b). 

  
 4 













 “Registration Rights Agreement” has the meaning set forth in the Recitals.

 “Registrable Securities” has the meaning set forth in the Registration Rights Agreement. 

“Registration Statement” means a registration statement meeting the requirements set forth in the Registration Rights
Agreement and covering the resale by the Purchasers of the Registrable Securities. 
 “Regulation D” has the meaning set
forth in the Recitals. 
 “Required Approvals” has the meaning set forth in Section 3.1(e). 

“Rule 144” means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended from time
to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same effect as such Rule. 

“SEC Reports” has the meaning set forth in Section 3.1(g). 

“Secretary’s Certificate” has the meaning set forth in 2.3(a)(vii). 

“Securities” has the meaning set forth in the Recitals. 

“Securities Act” has the meaning set forth in the Recitals. 

“Series A Preferred Stock” has the meaning set forth in the Recitals, and also includes any other class of securities into
which the Series A Preferred Stock may hereafter be reclassified or changed into. 
 “Short Sales” include, without
limitation, (i) all “short sales” as defined in Rule 200 promulgated under Regulation SHO under the Exchange Act, whether or not against the box, and all types of direct and indirect stock pledges, forward sale contracts, options,
puts, calls, short sales, swaps, “put equivalent positions” (as defined in Rule 16a-1(h) under the Exchange Act) and similar arrangements (including on a total return basis), and (ii) sales and
other transactions through non-U.S. broker dealers or non-U.S. regulated brokers (but shall not be deemed to include the location and/or reservation of borrowable shares
of Common Stock). 
 “Subscription Amount” means, with respect to each Purchaser, the aggregate amount to be paid for the
Securities purchased hereunder as indicated on Annex A opposite such Purchaser’s name, in United States dollars and in immediately available funds. 

“Subsidiary” means any subsidiary of the Company, and shall, where applicable, include any subsidiary of the Company formed
or acquired after the date hereof. 
 “Trading Affiliate” has the meaning set forth in
Section 3.2(h). 
 “Trading Day” means a day on which the principal Trading Market is open for
business. 
 “Trading Market” means any of the following markets or exchanges on which the Common Stock is listed or quoted
for trading on the date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, or the New York Stock Exchange (or any successors to any of the foregoing). 

  
 5 













 “Transaction Documents” means this Agreement, the schedules and exhibits
attached hereto, the Registration Rights Agreement, the Irrevocable Transfer Agent Instructions and any other documents or agreements explicitly contemplated hereunder. 

“Transfer Agent” means Computershare Trust Company, N.A., the current transfer agent of the Company, or any successor
transfer agent for the Company. 
 ARTICLE II. 

PURCHASE AND SALE 
 2.1
Purchase and Sale. On the Closing Date, upon the terms and subject to the conditions set forth herein, the Company will issue and sell to the Purchasers, and the Purchasers will purchase, severally and not jointly, the number of Securities
set forth opposite the name of such Purchaser under the heading “Number of Securities Purchased” on Annex A attached hereto for an aggregate purchase price of $104,400,000 (the “Purchase Price”). 

2.2 Closing. 
 (a)
Closing. Upon the satisfaction of the conditions set forth in Article V, the closing of the purchase and sale of the Securities (the “Closing”) shall take place remotely via exchange of executed documents and funds on
the third (3rd) Business Day after the date hereof, or at such other time and place as the Company may designate by notice to the Purchasers (such date and time being referred to herein as the “Closing Date”). 

(b) Payment. On or prior to the Closing Date, each Purchaser shall deliver to the Company the Subscription Amount via wire transfer of
immediately available funds to an account designated in writing by the Company or by other means approved by the Company on or prior to the Closing Date. At the Closing, following the receipt by the Company of the entire portion of the Subscription
Amount payable by a Purchaser, the Company shall deliver to such Purchaser copies of (a) a certificate evidencing the number of Securities set forth opposite such Purchaser’s name on Annex A, registered in the name of such Purchaser
and bearing the legend set forth in Section 4.1(b) (the original of such certificate to be delivered to such Purchaser as promptly as practicable after the Closing Date but in no event more than three (3) Business Days
after the Closing Date) and (b) a certificate from the Secretary of State of the State of Delaware evidencing the filing of the Certificate of Designations substantially in the form attached hereto as Exhibit A. 

2.3 Closing Deliverables. 

(a) On or prior to the Closing, the Company shall issue, deliver or cause to be delivered to each Purchaser the following (the “Company
Deliverables”): 
 (i) this Agreement, duly executed by the Company; 

(ii) evidence of the issuance of the Securities in the name of the Purchasers by book entry on the stock ledger of the Company (or, if the
Securities are to be represented in certificated form, a certificate representing the Securities in the name of such Purchaser as set forth on the Stock Certificate Questionnaire included as Exhibit C hereto (the “Stock
Certificate”)). 
 (iii) a legal opinion of Company Counsel, dated as of the Closing Date and in form and substance reasonably
satisfactory to the Purchasers, executed by such counsel and addressed to the Purchasers and the Placement Agent; 

  
 6 













 (iv) the Registration Rights Agreement, duly executed by the Company; 

(v) duly executed Irrevocable Transfer Agent Instructions acknowledged in writing by the Transfer Agent instructing the Transfer Agent to
deliver, on an expedited basis, a certificate evidencing a number of Securities equal to such Purchaser’s Subscription Amount divided by the Purchase Price, registered in the name of such Purchaser; 

(vi) the Company shall have filed with Nasdaq a Notification Form: Listing of Additional Shares for the listing of the Securities and the
Conversion Shares and shall have received confirmation from Nasdaq that it has completed its review of such form with no objections to the transactions contemplated herein. 

(vii) a certificate of the Secretary of the Company (the “Secretary’s Certificate”), dated as of the
Closing Date, (a) certifying the resolutions adopted by the Board of Directors of the Company or a duly authorized committee thereof approving the transactions contemplated by this Agreement and the other Transaction Documents and the issuance
of the Securities and the Conversion Shares, (b) certifying the current versions of the certificate of incorporation, as amended, and bylaws of the Company and (c) certifying as to the signatures and authority of persons signing the
Transaction Documents and related documents on behalf of the Company, in substantially the form attached hereto as Exhibit E; 

(viii) the Compliance Certificate referred to in Section 5.1(h); 

(ix) a certificate evidencing the formation and good standing of the Company issued by the Secretary of State of the State of Delaware, as of
a date within three (3) Business Days of the Closing Date; 
 (x) a certificate evidencing the Company’s qualification as a
foreign corporation and good standing issued by the Secretary of State (or comparable office) of each jurisdiction in which the Company is qualified to do business as a foreign corporation, as of a date within three (3) Business Days of the
Closing Date; and 
 (xi) a certified copy of the Certificate of Designations, as filed with the Secretary of State of the State of
Delaware. 
 (b) On or prior to the Closing, each Purchaser shall deliver or cause to be delivered to the Company the following (the
“Purchaser Deliverables”): 
 (i) this Agreement, duly executed by such Purchaser; 

(ii) its Subscription Amount, in United States dollars and in immediately available funds, in the amount set forth in the “Aggregate
Purchase Price (Subscription Amount)” column opposite each Purchaser’s name in the table set forth on Annex A by wire transfer to the Company; 

(iii) the Registration Rights Agreement, duly executed by such Purchaser; 

(iv) a fully completed and duly executed Selling Stockholder Questionnaire in the form attached as Annex B to the Registration Rights
Agreement; and 
 (v) a fully completed and duly executed Stock Certificate Questionnaire in the form attached hereto as Exhibit C.


  
 7 













 ARTICLE III. 

REPRESENTATIONS AND WARRANTIES 

3.1 Representations and Warranties of the Company. Except as previously disclosed in the SEC Reports (as defined below), the Company
hereby represents and warrants the following as of the date hereof and the Closing Date (except for the representations and warranties that speak as of a specific date, which shall be made as of such date) to each of the Purchasers and to the
Placement Agent: 
 (a) Due Organization; Subsidiaries. Each of the Company and its subsidiaries is a corporation or limited
liability company duly incorporated or formed, validly existing and in good standing under the Laws of the jurisdiction of its incorporation or organization and has all necessary corporate power and authority: (i) to conduct its business in the
manner in which its business is currently being conducted, (ii) to own or lease and use its property and assets in the manner in which its property and assets are currently owned or leased and used and (iii) to perform its obligations
under all Contracts by which it is bound. All of the Company’s Subsidiaries are wholly owned by the Company. Each of the Company and its subsidiaries is licensed and qualified to do business, and is in good standing (to the extent applicable in
such jurisdiction), under the Laws of all jurisdictions where the nature of its business in the manner in which its business is currently being conducted requires such licensing or qualification other than in jurisdictions where the failure to be so
qualified individually or in the aggregate would not be reasonably expected to have a Material Adverse Effect. 
 (b) Authorization;
Enforcement; Validity. The Company has the requisite corporate power and authority to enter into the Transaction Documents and, subject to receipt of the Requisite Stockholder Approval, to consummate the transactions contemplated hereby or
thereby. Subject to the receipt of the Requisite Stockholder Approval, all corporate action on the part of the Company, its directors and stockholders necessary for the authorization, execution, sale, issuance and delivery of the Securities and the
Conversion Shares contemplated herein has been taken. Each of the Transaction Documents to which the Company is a party have been (or upon delivery will have been) duly executed and delivered by the Company and is, or when delivered in accordance
with the terms hereof or thereof, will constitute the legal, valid and binding obligation of the Company enforceable against the Company in accordance with its respective terms, except (i) as such enforceability may be limited by applicable
bankruptcy, examinership, insolvency, reorganization, moratorium, liquidation or similar laws relating to, or affecting generally the enforcement of, creditors’ rights and remedies or by other equitable principles of general application,
(ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable law. 

(c) No Conflicts. The execution, delivery and performance by the Company of the Transaction Documents to which it is a party and the
issuance, sale and delivery of the Securities to be sold by the Company under the Transaction Documents (including, subject to the Company obtaining Requisite Stockholder Approval, the issuance of Conversion Shares upon the conversion of the
Securities), the performance by the Company of its obligations under the Transaction Documents and the consummation of the transactions contemplated hereby or thereby (including without limitation, the issuance of the Securities and the reservation
for issuance of the Conversion Shares) do not and will not (a) conflict with, result in the breach or violation of, or constitute (with or without the giving of notice or the passage of time or both) a violation of, or default under,
(i) any bond, debenture, note or other evidence of indebtedness, or under any lease, license, franchise, permit, indenture, mortgage, deed of trust, loan agreement, joint venture or other agreement or instrument to which the Company or any of
its Subsidiaries is a party or by which it or its properties may be bound or affected, (ii) the Company’s restated certificate of incorporation, as amended and as in effect on the date hereof (the “Certificate of
Incorporation”), the Company’s bylaws, as amended and as in effect on the date hereof (the “Bylaws”), or the equivalent document with respect to any of the Company’s Subsidiaries, as amended and as in effect on
the date hereof, or (iii) subject to the Requisite 

  
 8 













 
Stockholder Approval, any statute or law, judgment, decree, rule, regulation, ordinance or order of any court or governmental or regulatory body (including the Nasdaq), governmental agency,
arbitration panel or authority applicable to the Company, any of its subsidiaries or their respective properties, except in the case of clauses (i) and (iii) for such conflicts, breaches, violations or defaults that would not reasonably be
expected to have, individually or in the aggregate, a Material Adverse Effect. 
 (d) Filings, Consents and Approvals. Except for any
Current Report on Form 8-K, Notice of Exempt Offering of Securities on Form D to be filed by the Company in connection with the transaction contemplated hereby, any required filing with the Nasdaq and the
Required Stockholder Approval and the registration statement required to be filed by the Registration Rights Agreement, neither the Company nor any of its Subsidiaries is required to give any notice to, or make any filings with, or obtain any
authorization, consent, or approval of any government or governmental agency in order to consummate the transactions contemplated by the Transaction Documents. Assuming the accuracy of the representations of the Purchasers in
Section 3.2, no consent, approval, authorization or other order of, or registration, qualification or filing with, any court, regulatory body, administrative agency, self-regulatory organization, stock exchange or market
(including Nasdaq), or other governmental body is required for the execution and delivery of the Transaction Documents, the valid issuance, sale and delivery of the Securities to be sold pursuant to the Transaction Documents (including, subject to
the Company obtaining the Requisite Stockholder Approval, the issuance of Conversion Shares upon conversion of the Securities) other than such as have been or will be made or obtained, or for any securities filings required to be made under federal
or state securities laws applicable to the offering of the Securities or the issuance of Conversion Shares upon conversion of the Securities (other than the Requisite Stockholder Approval and filings that have been made, or will be made, pursuant to
the rules and regulations of Nasdaq). The Company and its Subsidiaries are unaware of any facts or circumstances that might prevent the Company from obtaining or effecting any of the registration, application or filings pursuant to this
Section 3.1(d). 
 (e) Issuance of the Securities. The issuance of the Securities has been duly authorized
and the Securities, when issued and paid for in accordance with the terms of the Transaction Documents, will be duly and validly issued, fully paid and nonassessable and free and clear of any Encumbrances, preemptive rights or restrictions (other
than as provided in this Agreement or any restrictions on transfer generally imposed under applicable securities laws). Subject to receipt of the Requisite Stockholder Approval, the Conversion Shares, when issued in accordance with the terms of the
Certificate of Designations, will be duly authorized, validly issued, fully paid and non-assessable, and shall be free and clear of any encumbrances, preemptive rights or restrictions (other than as provided
in this Agreement or any restrictions on transfer generally imposed under applicable securities laws). Upon receipt of the Requisite Stockholder Approval, the Company shall have reserved such number of shares of Common Stock sufficient to enable the
full conversion of all of the Securities. 
 (f) Capitalization. 

(i) As of July 2, 2020 (the “Capitalization Date”), the authorized capital stock of the Company consisted of (i)
10,000,000 shares of preferred stock, par value $0.001 per share (the “Preferred Stock”), none of which were issued and outstanding and (ii) 150,000,000 shares of Common Stock, 31,195,114 shares of which were issued and outstanding.
The Preferred Stock and the Common Stock are collectively referred to herein as the “Capital Stock.” All of the issued and shares of Capital Stock have been duly authorized and validly issued, and are fully paid and nonassessable
and are free of any Encumbrances. As of the Capitalization Date, the Company has reserved 8,676,700 shares of Common Stock for issuance under the Company’s 2015 Stock Incentive Plan, as amended (the “2015 Plan”) and the
Company’s 2018 Stock Option and Incentive Plan (the “2018 Plan” and, together with the 2015 Plan, the “Stock Plans”), of which 1,843,809 shares have been issued and are currently outstanding, 1,970,154 shares
have been reserved for issuance upon exercise or settlement of Company options and restricted stock units, 

  
 9 













 
as applicable, granted under the Stock Plans and 4,862,737 shares remain available for future issuance pursuant to the Stock plans. As of the date hereof, the Company has reserved 921,211 shares
of Common Stock for future issuance pursuant to the Company’s Employee Stock Purchase Plan (of which 90,184 shares have been issued and are currently outstanding). As of the date hereof, the Company has declared a distribution of one contingent
value right for each outstanding share of Common Stock as of immediately prior to the closing of the Merger, representing the right to receive contingent payments, payable in cash or Common Stock, upon the occurrence of certain events relating to
the sale of the Company’s non-cash assets (the “CVRs”).. After giving effect to the Merger and the issuance of the Securities, the Company will have 164,000 shares of Series A Preferred
Stock authorized, 163,324 of which will be issued and outstanding. All of the outstanding share capital of the Company has been duly authorized and validly issued, are fully paid and nonassessable. None of the outstanding shares of the Company were
issued in violation of any preemptive rights, rights of first refusal or other similar rights to subscribe for or purchase securities of the Company. Except as otherwise set forth in this Agreement or in the Merger Agreement, as of the date hereof
there are no outstanding options, warrants, rights (including conversion or preemptive rights), agreements, arrangements or commitments of any character, whether or not contingent, relating to the issued or unissued Capital Stock of the Company or
obligating the Company to issue or sell any share of Capital Stock of, or other equity interest in, the Company. 
 (ii) Effective as of the
consummation of the Merger, Kiq will be a wholly- owned subsidiary of the Company. 
 (g) SEC Reports; Disclosure Materials. The
Company has filed or furnished, as applicable, on a timely basis all forms, statements, certifications, reports and documents required to be filed or furnished by it with the Commission under the Exchange Act or the Securities Act since January 1,
2018 (the “SEC Reports”). As of the time it was filed with the Commission (or, if amended or superseded by a filing prior to the date of this Agreement, then on the date of such filing), each of the SEC Reports complied in all
material respects with the applicable requirements of the Securities Act or the Exchange Act (as the case may be) and as of the time they were filed, none of the SEC Reports contained any untrue statement of a material fact or omitted to state a
material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. 

(h) Financial Statements. As of their respective filing dates, the financial statements (including any related notes) contained or
incorporated by reference in the SEC Reports (i) complied as to form in all material respects with the Securities Act and the Exchange Act, as applicable, and the published rules and regulations of the Commission applicable thereto,
(ii) were prepared in accordance with GAAP (except as may be indicated in the notes to such financial statements or, in the case of unaudited financial statements, as permitted by Form 10-Q of the
Commission, and except that the unaudited financial statements may not contain footnotes and are subject to normal and recurring year-end adjustments that are not reasonably expected to be material in amount)
applied on a consistent basis unless otherwise noted therein throughout the periods indicated and (iii) fairly present, in all material respects, the consolidated financial position of the Company as of the respective dates thereof and the
results of operations and cash flows of the Company for the periods covered thereby. Other than as expressly disclosed in the SEC Reports filed prior to the date hereof, there has been no material change in the Company’s accounting methods or
principles that would be required to be disclosed in the Company’s financial statements in accordance with GAAP. Except as set forth in the consolidated financial statements of the Company included in the SEC Reports filed prior to the date
hereof, the Company has not incurred any liabilities, contingent or otherwise, except those incurred in the ordinary course of business, consistent (as to amount and nature) with past practices since the date of such financial statements, none of
which, individually or in the aggregate, have had or would reasonably be expected to have a Material Adverse Effect. The books of account and other financial records of the Company and each of its Subsidiaries are true and complete in all material
respects. 

  
 10 













 (i) Independent Accountants. PricewaterhouseCoopers LLP, who have certified certain
financial statements of the Company and delivered their report with respect to the audited financial statements included in the SEC Reports, has at all times since the date of enactment of the Sarbanes-Oxley Act been (i) a registered public
accounting firm (as defined in Section 2(a)(12) of the Sarbanes-Oxley Act), (ii) to the Knowledge of the Company, “independent” with respect to the Company within the meaning of Regulation S-X
under the Exchange Act and (iii) to the Knowledge of the Company, in compliance with subsections (g) through (l) of Section 10A of the Exchange Act and the rules and regulations promulgated by the Commission and the Public Accounting
Oversight Board thereunder. 
 (j) Absence of Certain Changes. Since March 31, 2020, there has been no material adverse change to, and
no material adverse development in, the business, properties, operations, condition (financial or otherwise), results of operations or prospects of the Company or its Subsidiaries. Since March 31, 2020, neither the Company nor any of its
Subsidiaries has (i) declared or paid any dividends, other than the CVRs, (ii) sold any material assets, individually or in the aggregate, outside of the ordinary course of business or (iii) had material capital expenditures,
individually or in the aggregate, outside of the ordinary course of business. Neither the Company nor any of its Subsidiaries has taken any steps to seek protection pursuant to any bankruptcy law nor does the Company have any knowledge or reason to
believe that its creditors intend to initiate involuntary bankruptcy proceedings or any actual knowledge of any fact that would reasonably lead any such creditor to do so. The Company and its Subsidiaries, individually and on a consolidated basis,
are not as of the date hereof, and after giving effect to the transactions contemplated hereby to occur at the Closing, will not be Insolvent (as defined below). For purposes of this Section 3.1(j), “Insolvent” means, with
respect to any Person, (i) the present fair saleable value of such Person’s assets is less than the amount required to pay such Person’s total Indebtedness, (ii) such Person is unable to pay its debts and liabilities,
subordinated, contingent or otherwise, as such debts and liabilities become absolute and matured, (iii) such Person intends to incur or believes that it will incur debts that would be beyond its ability to pay as such debts mature or
(iv) such Person has unreasonably small capital with which to conduct the business in which it is engaged as such business is now conducted and is proposed to be conducted. 

(k) Litigation. There is no action, suit, proceeding or investigation pending or, to the Company’s Knowledge, currently threatened
in writing against the Company or any of its directors and officers that questions the validity of the Transaction Documents or the right of the Company to enter into the Transaction Documents or to consummate the transactions contemplated hereby.
There is no action, suit, proceeding or investigation pending or, to the Company’s knowledge, currently threatened in writing against the Company or any Subsidiary or any of their respective directors and officers which would have, either
individually or in the aggregate, a Material Adverse Effect. 
 (l) Conduct of Business; Regulatory Permits. Neither the Company nor
any of its Subsidiaries is in violation of any term of or in default under its Certificate of Incorporation, any certificate of designations of any outstanding series of preferred stock of the Company or the Bylaws or their organizational charter or
bylaws, respectively. Neither the Company nor any of its Subsidiaries is in violation of any judgment, decree or order or any statute, ordinance, rule or regulation applicable to the Company or its Subsidiaries, and neither the Company nor any of
its Subsidiaries will conduct its business in violation of any of the foregoing, except for possible violations which would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. Without limiting the
generality of the foregoing, except as disclosed in the SEC Reports, the Company is not in violation of any of the rules, regulations or requirements of the Nasdaq and has no knowledge of any facts or circumstances that would reasonably lead to
delisting or suspension of the Common Stock by Nasdaq in the foreseeable future. The Company and its Subsidiaries possess all certificates, authorizations and permits issued by the appropriate regulatory authorities necessary to conduct their
respective businesses as currently conducted, except where the failure to possess such certificates, authorizations or permits would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect, and neither the
Company nor any such Subsidiary has received any written notice of proceedings relating to the revocation or modification of any such certificate, authorization or permit. 

  
 11 













 (m) Title to Assets. Each of the Company and its Subsidiaries owns, and has good and
marketable title to, or, in the case of leased properties and assets, valid leasehold interests in, all tangible properties or tangible assets and equipment used or held for use in its business or operations or purported to be owned by it,
including: (a) all tangible assets reflected on the Company’s Unaudited Interim Balance Sheet and (b) all other tangible assets reflected in the books and records of the Company as being owned by the Company. All of such assets are
owned or, in the case of leased assets, leased by the Company or any of its Subsidiaries free and clear of any Encumbrances, other than Permitted Encumbrances. 

(n) Intellectual Property Rights. Except as otherwise disclosed in the SEC Reports, the Company and its Subsidiaries own, or have
obtained valid and enforceable licenses for, the inventions, patent applications, patents, trademarks, trade names, service names, copyrights, trade secrets and other intellectual property described in the SEC Reports as being owned or licensed by
them or which are necessary for the conduct of their respective businesses as currently conducted or as currently proposed to be conducted (collectively, “Intellectual Property”) and the conduct of their respective businesses does
not and will not infringe, misappropriate or otherwise conflict in any material respect with any such rights of others. To the Company’s knowledge, the operation of the business of the Company, as now conducted or as proposed to be conducted in
the SEC Reports, together with the Company’s use of the Company’s Intellectual Property, does not conflict with, infringe, misappropriate or otherwise violate the Intellectual Property of any third party. Except as disclosed in the SEC
Reports, no actions, suits, claims or proceedings have been asserted, or, to the best of our knowledge, threatened against the Company alleging any of the foregoing or seeking to challenge, deny or restrict the operation of the business of the
Company and the Company is unaware of any facts which would form a reasonable basis for any such claim. Except as disclosed in the SEC Reports, the Company has not received any notice of a claim of infringement, misappropriation or conflict with
Intellectual Property Rights of others, except for such claims that would not, individually or the in aggregate, be reasonably expected to have a Material Adverse Effect. Except as disclosed in the SEC Reports, the Intellectual Property Rights owned
by the Company and, to the knowledge of the Company, any Intellectual Property Rights licensed to the Company have not been adjudged invalid or unenforceable, in whole or in part, and there is no pending or, to the Company’s knowledge,
threatened action, suit, proceeding or claim by others challenging the validity or scope of any such Intellectual Property Rights, and the Company is unaware of any facts which would form a reasonable basis for any such challenge, except for such
actions, suits, proceedings, or claims that would not, individually or the in aggregate, be reasonably expected to have a Material Adverse Effect. Except as otherwise disclosed in the SEC Reports, the Company is not a party to or bound by any
options, licenses or agreements with respect to the Intellectual Property Rights of any other person or entity that are required to be set forth in the SEC Reports. None of the technology or intellectual property used by the Company in its business
has been obtained or is being used by the Company in violation of any contractual obligation binding on the Company or, to the Company’s knowledge, any of its officers, directors or employees or otherwise in violation of the rights of any
persons. 
 (o) Insurance. Each of the Company and its Subsidiaries are insured by recognized, financially sound and reputable
institutions with policies in such amounts and with such deductibles and covering such risks as are generally deemed adequate and customary for their businesses including, but not limited to, policies covering real and personal property owned or
leased by the Company and its subsidiaries against theft, damage, destruction, acts of vandalism and earthquakes and policies covering the Company and its subsidiaries for product liability claims and clinical trial liability claims. The Company has
no reason to believe that it or any of its subsidiaries will not be able to (i) renew its existing insurance coverage as and when such policies expire or (ii) obtain comparable coverage from similar institutions as may be necessary or
appropriate to conduct its business as now conducted and at a cost that could not be expected to result in a Material Adverse Change. Neither the Company nor any of its subsidiaries has been denied any insurance coverage which it has sought or for
which it has applied. 

  
 12 













 (p) Transactions with Affiliates and Employees. Except as set forth in the SEC
Reports, since the date of the Company’s last proxy statement filed in 2020 with the SEC, no event has occurred that would be required to be reported by the Company pursuant to Item 404 of Regulation S-K
promulgated by the SEC. 
 (q) Company’s Accounting System. The Company and each of its Subsidiaries make and keep accurate books
and records, maintains disclosure controls and procedures and internal control over financial reporting (as defined in Rules 13a-15 and 15d-15 under the Exchange Act)
sufficient to provide reasonable assurance that: (i) transactions are executed in accordance with management’s general or specific authorization; (ii) transactions are recorded as necessary to permit preparation of financial
statements in conformity with generally accepted accounting principles as applied in the United States and to maintain accountability for assets; (iii) access to assets is permitted only in accordance with management’s general or specific
authorization; (iv) the recorded accountability for assets is compared with existing assets at reasonable intervals and appropriate action is taken with respect to any differences; and (v) the interactive data in eXtensible Business
Reporting Language included or incorporated by reference in the SEC Reports fairly presents the information called for in all material respects and is prepared in accordance with the Commission’s rules and guidelines applicable thereto. 

(r) Sarbanes-Oxley. The Company is in compliance in all material respects with the applicable provisions of the Sarbanes-Oxley Act of
2002 and the rules and regulations promulgated thereunder. 
 (s) No Registration. Assuming the accuracy of each Purchaser’s
representations and warranties set forth in Section 3.2, no registration under the Securities Act is required for the offer and sale of the Securities by the Company to the Purchasers as contemplated hereby. 

(t) Certain Fees. No person or entity will have, as a result of the transactions contemplated by this Agreement, any valid right,
interest or claim against or upon the Company or a Purchaser for any commission, fee or other compensation pursuant to any agreement, arrangement or understanding entered into by or on behalf of the Company, other than the Placement Agent with
respect to the offer and sale of the Securities (which placement agent fees are being paid by the Company). The Purchasers shall have no obligation with respect to any fees or with respect to any claims made by or on behalf of other Persons for fees
of a type contemplated in this Section 3.1(t) that may be due in connection with the transactions contemplated by the Transaction Documents. The Company shall indemnify, pay, and hold each Purchaser harmless against, any
liability, loss or expense (including, without limitation, attorneys’ fees and out-of-pocket expenses) arising in connection with any such right, interest or claim.

 (u) Private Placement. Assuming the accuracy of the Purchasers’ representations and warranties set forth in
Section 3.2 of this Agreement no registration under the Securities Act is required for the offer and sale of the Securities by the Company to the Purchasers under the Transaction Documents. The issuance and sale of the
Securities hereunder does not contravene the rules and regulations of the Trading Market. 
 (v) Company Not an “Investment
Company.” The Company is not, and will not be, immediately after receipt of payment for the Securities, required to register as an “investment company” under the Investment Company Act of 1940, as amended (the “Investment
Company Act”). 

  
 13 













 (w) Registration Rights. Other than each of the Purchasers or as set forth in the SEC
Reports, no Person has any right to cause the Company to effect the registration under the Securities Act of any securities of the Company other than those securities which are currently registered on an effective registration statement on file with
the Commission. 
 (x) Listing and Maintenance Requirements. The Company’s Common Stock is registered pursuant to
Section 12(b) or 12(g) of the Exchange Act, and the Company has taken no action designed to terminate the registration of the Common Stock under the Exchange Act, nor has the Company received any notification that the Commission is
contemplating terminating such registration or listing. To the Company’s Knowledge, it is in compliance with all applicable listing requirements of the Principal Trading Market. 

(y) Disclosure. The Company confirms that it has not provided, and to the Company’s Knowledge, none of its officers or directors
nor any other Person acting on its or their behalf has provided, and it has not authorized the Placement Agent to provide, any Purchaser or its respective agents or counsel with any information that it believes constitutes material, non-public information except insofar as the existence, provisions and terms of the Transaction Documents and the proposed transactions hereunder may constitute such information, all of which will be disclosed by
the Company in the Press Release as contemplated by Section 4.4 hereof. The Company understands and confirms that the Purchasers will rely on the foregoing representations in effecting transactions in securities of the
Company. 
 (z) No Integrated Offering. Assuming the accuracy of the Purchasers’ representations and warranties set forth in
Section 3.2, and except with respect to the capital stock to be issued pursuant to the Merger Agreement, none of the Company, its Subsidiaries nor, to the Company’s Knowledge, any of its Affiliates or any Person acting
on its behalf has, directly or indirectly, at any time within the past six (6) months, made any offers or sales of any Company security or solicited any offers to buy any security under circumstances that would (i) eliminate the
availability of the exemption from registration under Regulation D under the Securities Act in connection with the offer and sale by the Company of the Securities as contemplated hereby or (ii) cause the offering of the Securities pursuant to
the Transaction Documents to be integrated with prior offerings by the Company for purposes of any applicable law, regulation or stockholder approval provisions, including, without limitation, under the rules and regulations of any Trading Market on
which any of the securities of the Company are listed or designated. 
 (aa) Tax Matters. Each of the Company and each of its
Subsidiaries has timely filed all income Tax Returns and all other material Tax Returns that were required to be filed by or with respect to it under applicable Law. All such Tax Returns were correct and complete in all material respects and have
been prepared in material compliance with all applicable Law. Subject to exceptions as would not be material, no claim has ever been made by a Governmental Authority in a jurisdiction where the Company or any of its Subsidiaries does not file Tax
Returns that the Company or any of its Subsidiaries is subject to taxation by that jurisdiction. All material amounts of Taxes due and owing by the Company and each of its Subsidiaries (whether or not shown on any Tax Return) have been timely paid.
The unpaid Taxes of the Company and each of its Subsidiaries for periods (or portions thereof) ending on or prior to the date of the Unaudited Interim Balance Sheet do not materially exceed the accruals for current Taxes set forth on the Unaudited
Interim Balance Sheet. Since the date of the Unaudited Interim Balance Sheet, neither the Company nor any of its Subsidiaries has incurred any material Liability for Taxes outside the Ordinary Course of Business or otherwise inconsistent with past
custom and practice. 
 (bb) Compliance with Environmental Laws. Since January 1, 2018, the Company and each of its Subsidiaries has
complied with all applicable Environmental Laws, which compliance includes the possession by the Company of all permits and other Governmental Authorizations required under applicable Environmental Laws and compliance with the terms and conditions
thereof, except for any failure 

  
 14 













 
to be in compliance that, individually or in the aggregate, would not result in a Material Adverse Effect. Neither the Company nor any of its Subsidiaries has received since January 1, 2018, any
written notice or other communication (in writing or otherwise), whether from a Governmental Authority, citizens group, employee or otherwise, that alleges that the Company or any of its Subsidiaries is not in compliance with any Environmental Law,
and, to the Knowledge of the Company, there are no circumstances that may prevent or interfere with the Company’s or any of its Subsidiaries’ compliance with any Environmental Law in the future, except where such failure to comply would
not reasonably be expected to have a Material Adverse Effect. To the Knowledge of the Company: (i) no current or prior owner of any property leased or controlled by the Company or any of its Subsidiaries has received since January 1, 2018,
any written notice or other communication relating to property owned or leased at any time by the Company or any of its Subsidiaries, whether from a Governmental Authority, citizens group, employee or otherwise, that alleges that such current or
prior owner or the Company or any of its Subsidiaries is not in compliance with or violated any Environmental Law relating to such property and (ii) neither the Company nor any of its Subsidiaries has any material liability under any
Environmental Law. 
 (cc) No General Solicitation. Neither the Company nor, to the Company’s Knowledge, any person acting on
behalf of the Company has offered or sold any of the Securities by any form of general solicitation or general advertising. 
 (dd)
Anti-Corruption and Anti-Bribery Laws. Neither the Company nor any of its Subsidiaries nor any director, officer, or employee of the Company or any of its Subsidiaries, nor to the Company’s Knowledge, any agent, Affiliate or other
person acting on behalf of the Company or any of its subsidiaries has, in the course of its actions for, or on behalf of, the Company or any of its subsidiaries (i) used any corporate funds for any unlawful contribution, gift, entertainment or
other unlawful expenses relating to political activity; (ii) made or taken any act in furtherance of an offer, promise, or authorization of any direct or indirect unlawful payment or benefit to any
non-U.S. or domestic government official or employee, including of any government-owned or controlled entity or public international organization, or any political party, party official, or candidate for
political office; (iii) violated or is in violation of any provision of the U.S. Foreign Corrupt Practices Act of 1977, as amended (the “FCPA”), the UK Bribery Act 2010, or any other applicable anti-bribery or anti-corruption
law; or (iv) made, offered, authorized, requested, or taken an act in furtherance of any unlawful bribe, rebate, payoff, influence payment, kickback or other unlawful payment or benefit. The Company and its Subsidiaries and, to the
Company’s Knowledge, the Company’s Affiliates have conducted their respective businesses in compliance with the FCPA and have instituted and maintain policies and procedures designed to ensure, and which are reasonably expected to continue
to ensure, continued compliance therewith. 
 (ee) Money Laundering Laws. The operations of the Company and its subsidiaries are and
have been conducted at all times in compliance with applicable financial recordkeeping and reporting requirements of the USA Patriot Act, the Bank Secrecy Act of 1970, as amended, the money laundering statutes of all jurisdictions, the rules and
regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered or enforced by any governmental agency (collectively, the “Money Laundering Laws”); and no action, suit or proceeding by or
before any court or governmental agency, authority or body or any arbitrator or non-governmental authority involving the Company or its subsidiaries with respect to the Money Laundering Laws is pending or, to
the Company’s Knowledge, threatened. 
 (ff) OFAC. Neither the Company nor its subsidiaries nor any of their respective
affiliates, directors, officers, nor to the Company’s Knowledge, any agent or employee of the Company or its subsidiaries is subject to any sanctions administered or enforced by the Office of Foreign Assets Control (“OFAC”) of
the United States Treasury Department, the U.S. Department of State, the United Nations Security Council, the European Union, Her Majesty’s Treasury or any other relevant sanctions authority; and the Company will not directly or indirectly use
the proceeds of the offering of the Securities contemplated 

  
 15 













 
hereby, or lend, contribute or otherwise make available such proceeds to any subsidiary, joint venture partner or other person or entity for the purpose of financing the activities of any person
that is the target of sanctions administered or enforced by such authorities or in connection with any country or territory that is the target of country- or territory-wide OFAC sanctions (currently, Iran, Syria, Cuba, North Korea, and the Crimea
Region of Ukraine). 
 (gg) Off Balance Sheet Arrangements. There is no transaction, arrangement, or other relationship between the
Company (or any Subsidiary) and an unconsolidated or other off balance sheet entity that is required to be disclosed by the Company in SEC Reports and is not so disclosed and would have or reasonably be expected to result in a Material Adverse
Effect. 
 (hh) Acknowledgment Regarding Purchaser’s Purchase of Securities. The Company acknowledges and agrees that each
Purchaser is acting solely in the capacity of an arm’s length purchaser with respect to this Agreement and the other Transaction Documents and the transactions contemplated hereby and thereby, and that the obligations of each Purchaser under
this Agreement and the other Transaction Documents are several and not joint. The Company further acknowledges that no Purchaser is acting as a financial advisor or fiduciary of the Company or any of its Subsidiaries (or in any similar capacity)
with respect to this Agreement and the other Transaction Documents and the transactions contemplated hereby and thereby, and any advice given by a Purchaser or any of its representatives or agents in connection with this Agreement and the other
Transaction Documents and the transactions contemplated hereby and thereby is merely incidental to such Purchaser’s purchase of the Securities. The Company further represents to each Purchaser that the Company’s decision to enter into the
Transaction Documents has been based solely on the independent evaluation by the Company and its representatives. 
 (ii) No Price
Stabilization or Manipulation; Compliance with Regulation M. Neither the Company nor any of its Subsidiaries has taken, directly or indirectly, any action designed to or that might cause or result in stabilization or manipulation of the price of
the any security of the Company to facilitate the sale or resale of the Securities or otherwise, and has taken no action which would directly or indirectly violate Regulation M under the Exchange Act. 

(jj) Clinical Data and Regulatory Compliance. The preclinical tests and clinical trials, and other studies
(collectively, “studies”) that are described in, or the results of which are referred to in, the SEC Reports were and, if still pending, are being conducted in all material respects in accordance with the protocols, procedures and controls
designed and approved for such studies and with standard medical and scientific research procedures; each description of the results of such studies is accurate and complete in all material respects and fairly presents the data derived from such
studies, and the Company and its Subsidiaries have no knowledge of any other studies the results of which are inconsistent with, or otherwise call into question, the results described or referred to in the SEC Reports; the Company and its
Subsidiaries have made all such filings and obtained all such approvals as may be required by the Food and Drug Administration of the U.S. Department of Health and Human Services or any committee thereof or from any other U.S. or non-U.S. government or drug or medical device regulatory agency, or health care facility Institutional Review Board (collectively, the “Regulatory Agencies”); neither the Company nor any of its
Subsidiaries has received any notice of, or correspondence from, any Regulatory Agency requiring the termination, suspension or modification of any clinical trials that are described or referred to in the SEC Reports; and the Company and its
Subsidiaries have each operated and currently are in compliance in all material respects with all applicable rules, regulations and policies of the Regulatory Agencies. 

(kk) No Additional Agreements. The Company does not have any agreement or understanding with any Purchaser with respect to the
transactions contemplated by the Transaction Documents other than as specified in the Transaction Documents. 

  
 16 













 (ll) No Disqualification Events. No “bad actor” disqualifying event
described in Rule 506(d)(1)(i)-(viii) of the Securities Act (a “Disqualification Event”) is applicable to the Company or, to the Company’s Knowledge, any Company Covered Person (as defined below), except for a Disqualification
Event as to which Rule 506(d)(2)(ii–iv) or (d)(3), is applicable. “Company Covered Person” means, with respect to the Company as an “issuer” for purposes of Rule 506 promulgated under the Securities Act, any person
listed in the first paragraph of Rule 506(d)(1). Other than the Placement Agent, the Company is not aware of any Person (other than any Company Covered Person) that has been or will be paid (directly or indirectly) remuneration for solicitation of
purchasers in connection with the sale of the Securities pursuant to this Agreement. The Company has complied, to the extent applicable, with its disclosure obligations under Rule 506(e), and has furnished to the Placement Agent a copy of any
disclosures provided thereunder. 
 3.2 Representations and Warranties of the Purchasers. Each Purchaser hereby, for itself and for no
other Purchaser, represents and warrants as of the date hereof and as of the Closing Date to the Company and the Placement Agent as follows: 

(a) Organization; Authority. Such Purchaser is an entity duly organized, validly existing and in good standing under the laws of the
jurisdiction of its organization with the requisite corporate or partnership power and authority to enter into and to consummate the transactions contemplated by the applicable Transaction Documents and otherwise to carry out its obligations
hereunder and thereunder. The execution and delivery of this Agreement by such Purchaser and performance by such Purchaser of the transactions contemplated by this Agreement have been duly authorized by all necessary corporate or, if such Purchaser
is not a corporation, such partnership, limited liability company or other applicable like action, on the part of such Purchaser. Each Transaction Document to which it is a party has been duly executed by such Purchaser, and when delivered by such
Purchaser in accordance with the terms hereof, will constitute the valid and legally binding obligation of such Purchaser, enforceable against it in accordance with its terms, except as such enforceability may be limited by applicable bankruptcy,
insolvency, reorganization, moratorium, liquidation or similar laws relating to, or affecting generally the enforcement of, creditors’ rights and remedies or by other equitable principles of general application. 

(b) No Conflicts. The execution, delivery and performance by such Purchaser of this Agreement and the Registration Rights Agreement and
the consummation by such Purchaser of the transactions contemplated hereby and thereby will not (i) result in a violation of the organizational documents of such Purchaser, (ii) conflict with, or constitute a default (or an event which
with notice or lapse of time or both would become a default) under, or give to others any rights of termination, amendment, acceleration or cancellation of, any agreement, indenture or instrument to which such Purchaser is a party, or (iii) result
in a violation of any law, rule, regulation, order, judgment or decree (including U.S. federal and state securities laws) applicable to such Purchaser, except in the case of clauses (ii) and (iii) above, for such conflicts, defaults, rights or
violations which would not, individually or in the aggregate, reasonably be expected to have a material adverse effect on the ability of such Purchaser to perform its obligations hereunder. 

(c) Investment Intent. Such Purchaser understands that the Securities are “restricted securities” and have not been registered
under the Securities Act or any applicable U.S. state securities law and is acquiring the Securities as principal for its own account and not with a view to, or for distributing or reselling such Securities or any part thereof in violation of the
Securities Act or any applicable U.S. state or other securities laws, provided, however, that by making the representations herein, such Purchaser does not agree to hold any of the Securities for any minimum period of time and reserves the
right, subject to the provisions of this Agreement and the Registration Rights Agreement, at all times to sell or otherwise dispose of all or any part of such Securities pursuant to an effective registration statement under the Securities Act or
under an exemption from such registration and in compliance with applicable U.S. federal, state and other securities laws. Such Purchaser is acquiring the Securities hereunder in the ordinary course of its business.


  
 17 













 
Such Purchaser does not presently have any agreement, plan or understanding, directly or indirectly, with any Person to distribute or effect any distribution of any of the Securities (or any
securities which are derivatives thereof) to or through any person or entity; such Purchaser is not a registered broker-dealer under Section 15 of the Exchange Act or an entity engaged in a business that would require it to be so registered as
a broker-dealer. 
 (d) Purchaser Status. At the time such Purchaser was offered the Securities, it was, and at the date hereof it is,
an “accredited investor” as defined in Rule 501(a) under the Securities Act. 
 (e) General Solicitation. Such Purchaser is
not purchasing the Securities as a result of any advertisement, article, notice or other communication regarding the Securities published in any newspaper, magazine or similar media or broadcast over television or radio or presented at any seminar
or any other general advertisement. 
 (f) Experience of Such Purchaser. Such Purchaser, either alone or together with its
representatives, has such knowledge, sophistication and experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment in the Securities, and has so evaluated the merits and risks of
such investment. Such Purchaser is able to bear the economic risk of an investment in the Securities and, at the present time, is able to afford a complete loss of such investment. 

(g) Access to Information. Such Purchaser acknowledges that it has had the opportunity to review the SEC Reports and has been afforded
(i) the opportunity to ask such questions as it has deemed necessary of, and to receive answers from, representatives of the Company concerning the terms and conditions of the offering of the Securities and the merits and risks of investing in
the Securities; (ii) access to information about the Company and the Subsidiaries and their respective financial condition, results of operations, business, properties, management and prospects sufficient to enable it to evaluate its
investment; and (iii) the opportunity to obtain such additional information that the Company possesses or can acquire without unreasonable effort or expense that is necessary to make an informed investment decision with respect to the
investment. Neither such inquiries nor any other investigation conducted by or on behalf of such Purchaser or its representatives or counsel shall modify, amend or affect such Purchaser’s right to rely on the truth, accuracy and completeness of
the SEC Reports and the Company’s representations and warranties contained in the Transaction Documents. Such Purchaser has sought such accounting, legal and tax advice as it has considered necessary to make an informed decision with respect to
its acquisition of the Securities. 
 (h) Certain Trading Activities. Other than with respect to the transactions contemplated herein,
since the time that such Purchaser was first contacted by the Company, the Placement Agent or any other Person regarding the transactions contemplated hereby, neither the Purchaser nor any Affiliate of such Purchaser which (x) had knowledge of
the transactions contemplated hereby, (y) has or shares discretion relating to such Purchaser’s investments or trading or information concerning such Purchaser’s investments, including in respect of the Securities, and (z) is
subject to such Purchaser’s review or input concerning such Affiliate’s investments or trading (collectively, “Trading Affiliates”) has directly or indirectly, nor has any Person acting on behalf of or pursuant to any
understanding with such Purchaser or Trading Affiliate, effected or agreed to effect any purchases or sales of the securities of the Company (including, without limitation, any Short Sales involving the Company’s securities). Notwithstanding
the foregoing, in the case of a Purchaser and/or Trading Affiliate that is, individually or collectively, a multi-managed investment bank or vehicle whereby separate portfolio managers manage separate portions of such Purchaser’s or Trading
Affiliate’s assets and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers managing other portions of such Purchaser’s or Trading Affiliate’s assets, the representation set forth
above shall apply only with respect to the portion of assets managed by the portfolio manager that have knowledge about the financing transaction contemplated by this Agreement. Other than 

  
 18 













 
to other Persons party to this Agreement, such Purchaser has maintained the confidentiality of all disclosures made to it in connection with this transaction (including the existence and terms of
this transaction). Notwithstanding the foregoing, for avoidance of doubt, nothing contained herein shall constitute a representation or warranty, or preclude any actions, with respect to the identification of the availability of, or securing of,
available shares to borrow in order to effect Short Sales or similar transactions in the future. 
 (i) Brokers and Finders. Other
than the Placement Agent, no Person will have, as a result of the transactions contemplated by this Agreement, any valid right, interest or claim against or upon the Company or any Purchaser for any commission, fee or other compensation pursuant to
any agreement, arrangement or understanding entered into by or on behalf of the Purchaser. No Purchaser shall have any obligation with respect to any fees, or with respect to any claims made by or on behalf of other Persons for fees, in each case of
the type contemplated by this Section 3.2(i) that may be due in connection with the transactions contemplated by this Agreement or the Transaction Documents. 

(j) Independent Investment Decision. Such Purchaser has independently evaluated the merits of its decision to purchase Securities
pursuant to the Transaction Documents, and such Purchaser confirms that it has not relied on the advice of any other Purchaser’s business and/or legal counsel in making such decision. Such Purchaser understands that nothing in this Agreement or
any other materials presented by or on behalf of the Company to the Purchaser in connection with the purchase of the Securities constitutes legal, tax or investment advice. Such Purchaser has consulted such legal, tax and investment advisors as it,
in its sole discretion, has deemed necessary or appropriate in connection with its purchase of the Securities. Such Purchaser understands that the Placement Agent has acted solely as the agent of the Company in this placement of the Securities and
such Purchaser has not relied on the business or legal advice of the Placement Agent or any of its agents, counsel or Affiliates in making its investment decision hereunder, and confirms that none of such Persons has made any representations or
warranties to such Purchaser in connection with the transactions contemplated by the Transaction Documents. 
 (k) Reliance on
Exemptions. Such Purchaser understands that the Securities being offered and sold to it in reliance on specific exemptions from the registration requirements of United States federal and state securities laws and that the Company is relying in
part upon the truth and accuracy of, and such Purchaser’s compliance with, the representations, warranties, agreements, acknowledgements and understandings of such Purchaser set forth herein in order to determine the availability of such
exemptions and the eligibility of such Purchaser to acquire the Securities. 
 (l) No Governmental Review. Such Purchaser understands
that no United States federal or state agency or any other government or governmental agency has passed on or made any recommendation or endorsement of the Securities or the fairness or suitability of the investment in the Securities nor have such
authorities passed upon or endorsed the merits of the offering of the Securities. 
 (m) Regulation M. Such Purchaser is aware that
the anti-manipulation rules of Regulation M under the Exchange Act may apply to sales of Securities and other activities with respect to the Securities by the Purchasers. 

(n) Beneficial Ownership. The purchase by such Purchaser of the Securities issuable to it at the Closing will not result in such
Purchaser (individually or together with any other Person with whom such Purchaser has identified, or will have identified, itself as part of a “group” in a public filing made with the Commission involving the Company’s securities)
acquiring, or obtaining the right to acquire, beneficial ownership in excess of 19.999% of the outstanding shares of Common Stock or the voting power of the Company on a post transaction basis that assumes that such Closing shall have occurred. Such
Purchaser does not presently intend to, alone or together with others, make a public filing with the Commission to disclose that it has (or that it together with such other Persons have) acquired, or obtained the right to


  
 19 













 
acquire, as a result of such Closing (when added to any other securities of the Company that it or they then own or have the right to acquire), beneficial ownership in excess of 19.999% of the
outstanding shares of Common Stock or the voting power of the Company on a post transaction basis that assumes that each Closing shall have occurred. 

(o) Residency. Such Purchaser’s residence (if an individual) or offices in which its investment decision with respect to the
Securities was made (if an entity) are located at the address immediately below such Purchaser’s name on its signature page hereto. 
 The Company and
each of the Purchasers acknowledge and agree that no party to this Agreement has made or makes any representations or warranties with respect to the transactions contemplated hereby other than those specifically set forth in this Article III
and the Transaction Documents. 
 ARTICLE IV. 

OTHER AGREEMENTS OF THE PARTIES 

4.1 Transfer Restrictions. 

(a) Compliance with Laws. Notwithstanding any other provision of this Article IV, each Purchaser covenants that the Securities
and Conversion Shares may be disposed of only pursuant to an effective registration statement under, and in compliance with the requirements of, the Securities Act, or pursuant to an available exemption from, or in a transaction not subject to, the
registration requirements of the Securities Act, and in compliance with any applicable U.S. state and federal securities laws. In connection with any transfer of the Securities other than (i) pursuant to an effective registration statement,
(ii) to the Company, (iii) pursuant to Rule 144 (provided that the Purchaser provides the Company with reasonable assurances (in the form of seller and, if applicable, broker representation letters) that the securities may be sold
pursuant to such rule) or (iv) in connection with a bona fide pledge as contemplated in Section 4.1(b), the Company may require the transferor thereof to provide to the Company an opinion of counsel selected by the
transferor and reasonably acceptable to the Company, the form and substance of which opinion shall be reasonably satisfactory to the Company, to the effect that such transfer does not require registration of such transferred Securities under the
Securities Act. As a condition of transfer, any such transferee shall agree in writing to be bound by the terms of this Agreement and the Registration Rights Agreement and shall have the rights of a Purchaser under this Agreement and the
Registration Rights Agreement with respect to such transferred Securities. 
 (b) Legends. Certificates evidencing the Securities and
any Conversion Shares shall bear, any legend as required by the “blue sky” laws of any state and a restrictive legend in substantially the following form: 

THE SECURITIES REPRESENTED BY THIS CERTIFICATE TO WHICH THIS CONFIRMATION RELATES HAVE NOT BEEN REGISTERED UNDER THE
SECURITIES ACT OF 1933, AS AMENDED, OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE SECURITIES MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, HYPOTHECATED, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR
THE SECURITIES UNDER APPLICABLE SECURITIES LAWS, OR UNLESS OFFERED, SOLD, PLEDGED, HYPOTHECATED OR TRANSFERRED PURSUANT TO AN AVAILABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THOSE LAWS. THE COMPANY AND ITS TRANSFER AGENT SHALL BE ENTITLED
TO REQUIRE AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY AND THE TRANSFER AGENT THAT SUCH REGISTRATION IS NOT REQUIRED. 

  
 20 













 The Company acknowledges and agrees that a Purchaser may from time to time pledge, and/or
grant a security interest in, some or all of the legended Securities in connection with applicable securities laws, pursuant to a bona fide margin agreement in compliance with a bona fide margin loan. Such a pledge would not be subject to approval
or consent of the Company and no legal opinion of legal counsel to the pledgee, secured party or pledgor shall be required in connection with the pledge, but such legal opinion shall be required in connection with a subsequent transfer or
foreclosure following default by the Purchaser transferee of the pledge. No notice shall be required of such pledge, but Purchaser’s transferee shall promptly notify the Company of any such subsequent transfer or foreclosure. Each Purchaser
acknowledges that the Company shall not be responsible for any pledges relating to, or the grant of any security interest in, any of the Securities or for any agreement, understanding or arrangement between any Purchaser and its pledgee or secured
party. At the appropriate Purchaser’s expense, the Company will execute and deliver such reasonable documentation as a pledgee or secured party of Securities may reasonably request in connection with a pledge or transfer of the Securities,
including the preparation and filing of any required prospectus supplement under Rule 424(b)(3) of the Securities Act or other applicable provision of the Securities Act to appropriately amend the list of selling stockholders thereunder. Each
Purchaser acknowledges and agrees that, except as otherwise provided in Section 4.1(c), any Securities subject to a pledge or security interest as contemplated by this Section 4.1(b) shall continue
to bear the legend set forth in this Section 4.1(b) and be subject to the restrictions on transfer set forth in Section 4.1(a). 

(c) Removal of Legends. Upon request of the Purchaser or as contemplated under the Irrevocable Transfer Agent Instructions, upon receipt
by the Company of an opinion of counsel reasonably satisfactory to the Company to the effect that such legend is no longer required under the Securities Act and applicable state securities laws, the Company shall promptly cause the legend to be
removed from any certificate for any Conversion Shares in accordance with the terms of this Agreement and deliver, or cause to be delivered, to any Purchaser new certificate(s) representing the Conversion Shares that are free from all restrictive
and other legends or, at the request of such Investor, via DWAC transfer to such Purchaser’s account. 
 (d) Irrevocable Transfer
Agent Instructions. The Company shall issue irrevocable instructions to its transfer agent, and any subsequent transfer agent, in the form of Exhibit D attached hereto (the “Irrevocable Transfer Agent Instructions”). The
Company represents and warrants that no instruction other than the Irrevocable Transfer Agent Instructions referred to in this Section 4.1(d) (or instructions that are consistent therewith) will be given by the Company to
its Transfer Agent in connection with this Agreement, and that the Securities and Conversion Shares shall otherwise be freely transferable on the books and records of the Company as and to the extent provided in this Agreement and the other
Transaction Documents and applicable law. The Company acknowledges that a breach by it of its obligations under this Section 4.1(d) will cause irreparable harm to a Purchaser. Accordingly, the Company acknowledges that the
remedy at law for a breach of its obligations under this Section 4.1(d) may be inadequate and agrees, in the event of a breach or threatened breach by the Company of the provisions of this
Section 4.1(d), that a Purchaser shall be entitled, in addition to all other available remedies, to an order and/or injunction restraining any breach and requiring immediate issuance and transfer, without the necessity of
showing economic loss and without any bond or other security being required. 
 (e) Acknowledgement. Each Purchaser hereunder
acknowledges its primary responsibilities under the Securities Act and accordingly will not sell or otherwise transfer the Securities or Conversion Shares or any interest therein without complying with the requirements of the Securities Act. While
the Registration Statement remains effective, each Purchaser hereunder may sell the Conversion Shares in accordance with the plan of distribution contained in the Registration Statement and if it does so it


  
 21 













 
will comply therewith and with the related prospectus delivery requirements unless an exemption therefrom is available. Each Purchaser, severally and not jointly with the other Purchasers, agrees
that if it is notified by the Company in writing at any time that the Registration Statement registering the resale of the Conversion Shares is not effective or that the prospectus included in such Registration Statement is no longer compliant with
the requirements of Section 10 of the Securities Act, the Purchaser will refrain from selling such Conversion Shares until such time as the Purchaser is notified by the Company that such Registration Statement is effective or such prospectus is
compliant with Section 10 of the Securities Act, unless such Purchaser is able to, and does, sell such Conversion Shares pursuant to an available exemption from the registration requirements of Section 5 of the Securities Act. Both the
Company and its Transfer Agent, and their respective directors, officers, employees and agents, may rely on this Section 4.1(e) and each Purchaser hereunder will indemnify and hold harmless each of such persons from any
breaches or violations of this Section 4.1(e). 
 4.2 Furnishing of Information. In order to enable the
Purchasers to sell the Securities under Rule 144, for a period of twelve (12) months from the Closing, the Company shall use its commercially reasonable efforts to timely file (or obtain extensions in respect thereof and file within the
applicable grace period) all reports required to be filed by the Company after the date hereof pursuant to the Exchange Act. During such twelve (12) month period, if the Company is not required to file reports pursuant to the Exchange Act, it
will prepare and furnish to the Purchasers and make publicly available in accordance with Rule 144(c) such information as is required for the Purchasers to sell the Securities under Rule 144. 

4.3 Integration. The Company shall not, and shall use its commercially reasonable efforts to ensure that no Affiliate of the Company
shall, sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined in Section 2 of the Securities Act) that will be integrated with the offer or sale of the Securities in a manner that would
require the registration under the Securities Act of the sale of the Securities to the Purchasers, or that will be integrated with the offer or sale of the Securities for purposes of the rules and regulations of any Trading Market such that it would
require stockholder approval prior to the closing of such other transaction unless stockholder approval is obtained before the closing of such subsequent transaction; provided, however, that this Section 4.3 shall not limit the Company’s
right to issue shares of capital stock pursuant to the Merger Agreement. 
 4.4 Securities Laws Disclosure; Publicity. By 9:00 A.M.,
New York City time, on the Trading Day immediately following the date hereof, the Company shall issue a press release (the “Press Release”) reasonably acceptable to the Placement Agent disclosing all material terms of the
transactions contemplated hereby. On or before 9:00 A.M., New York City time, on the second (2nd) Trading Day immediately following the execution of this Agreement, the Company will file a Current Report on Form
8-K with the Commission describing the terms of the Transaction Documents (and including as exhibits to such Current Report on Form 8-K the material Transaction
Documents (including, without limitation, this Agreement and the Registration Rights Agreement)). Notwithstanding the foregoing, the Company shall not publicly disclose the name of any Purchaser or an Affiliate of any Purchaser, or include the name
of any Purchaser or an Affiliate of any Purchaser in any press release or filing with the Commission (other than the Registration Statement) or any regulatory agency or Trading Market, without the prior written consent of such Purchaser, except
(i) as required by U.S. federal securities law in connection with (A) any registration statement contemplated by the Registration Rights Agreement or (B) the filing of final Transaction Documents (including signature pages thereto)
with the Commission and (ii) to the extent such disclosure is required by law, request of the Commission’s staff or Trading Market regulations, in which case the Company shall provide the Purchasers with prior written notice of such
disclosure permitted under this subclause (ii). From and after the issuance of the Press Release, no Purchaser shall be in possession of any material, non-public information received from the Company, any
Subsidiary or any of their respective officers, directors, employees or agents, that is not disclosed in the Press Release. Each Purchaser, severally and not jointly with the other Purchasers, covenants that until such time as the transactions
contemplated by this Agreement are required to be publicly disclosed by the Company as described in this Section 4.4, such Purchaser will maintain the confidentiality of all disclosures made to it in connection with this
transaction (including the existence and terms of this transaction). 

  
 22 













 4.5 Shareholder Rights Plan. No claim will be made or enforced by the Company or,
with the consent of the Company, any other Person, that any Purchaser is an “Acquiring Person” under any control share acquisition, business combination, poison pill (including any distribution under a rights agreement) or similar
anti-takeover plan or arrangement or law (including Section 203 of the Delaware General Corporation Law) in effect or hereafter adopted by the Company, or that any Purchaser could be deemed to trigger the provisions of any such plan or
arrangement, in either case solely by virtue of receiving Securities or Conversion Shares under the Transaction Documents; provided, however, that no such Purchaser owns any equity in the Company prior to its purchase of the Securities hereunder.

 4.6 Non-Public Information. Except with respect to the material terms and conditions of the
transactions contemplated by the Transaction Documents, including this Agreement, or as expressly required by any applicable securities law, the Company covenants and agrees that neither it, nor any other Person acting on its behalf, will provide
any Purchaser or its agents or counsel with any information regarding the Company that the Company believes constitutes material non-public information without the express written consent of such Purchaser,
unless prior thereto such Purchaser shall have executed a written agreement regarding the confidentiality and use of such information. The Company understands and confirms that each Purchaser shall be relying on the foregoing covenant in effecting
transactions in securities of the Company. 
 4.7 Use of Proceeds. The Company shall use the net proceeds from the sale of the
Securities hereunder for working capital and general corporate purposes. 
 4.8 Principal Trading Market Listing. In the time and
manner required by the Principal Trading Market, the Company shall prepare and file with such Principal Trading Market an additional shares listing application covering all of the Securities and Conversion Shares and shall use its commercially
reasonable efforts to take all steps necessary to cause all of the Securities and Conversion Shares to be approved for listing on the Principal Trading Market as promptly as possible thereafter. 

4.9 Form D; Blue Sky. The Company agrees to timely file a Form D with respect to the Securities as required under Regulation D and to
provide a copy thereof, promptly upon the written request of any Purchaser. The Company, on or before the Closing Date, shall take such action as the Company shall reasonably determine is necessary in order to obtain an exemption for or to qualify
the Securities for sale to the Purchasers under applicable securities or “Blue Sky” laws of the states of the United States (or to obtain an exemption from such qualification) and shall provide evidence of such actions promptly upon the
written request of any Purchaser. 
 4.10 Delivery of Securities After Closing. The Company shall deliver, or cause to be delivered,
the respective Securities purchased by each Purchaser to such Purchaser within three (3) Trading Days of the Closing Date. 
 4.11
Short Sales and Confidentiality After The Date Hereof. Such Purchaser shall not, and shall cause its Trading Affiliates not to, engage, directly or indirectly, in any transactions in the Company’s securities (including, without
limitation, any Short Sales involving the Company’s securities) during the period from the date hereof until the earlier of such time as (i) the transactions contemplated by this Agreement are first publicly announced as required by and
described in Section 4.4 or (ii) this Agreement is terminated in full pursuant to Section 6.18. Each Purchaser, severally and not jointly with the other Purchasers, covenants that until such
time as the transactions contemplated by this Agreement are publicly disclosed by the Company as described in Section 4.4, such Purchaser will maintain the confidentiality of the existence and terms of this transaction and
the information included in the Transaction Documents. 

  
 23 













 Notwithstanding the foregoing, no Purchaser makes any representation, warranty or covenant hereby that it
will not engage in Short Sales in the securities of the Company after the time that the transactions contemplated by this Agreement are first publicly announced as described in Section 4.4; provided, however, each
Purchaser agrees, severally and not jointly with any Purchasers, that they will not enter into any Net Short Sales (as hereinafter defined) from the period commencing on the Closing Date and ending on the earliest of (x) the Effective Date of
the initial Registration Statement, (y) the twenty-four (24) month anniversary of the Closing Date or (z) the date that such Purchaser no longer holds any Securities. For purposes of this Section 4.12, a
“Net Short Sale” by any Purchaser shall mean a sale of Common Stock by such Purchaser that is marked as a short sale and that is made at a time when there is no equivalent offsetting long position in Common Stock held by such
Purchaser. Notwithstanding the foregoing, in the event that a Purchaser is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of such Purchaser’s assets and the portfolio managers have no direct
knowledge of the investment decisions made by the portfolio managers managing other portions of such Purchaser’s assets, the representation set forth above shall apply only with respect to the portion of assets managed by the portfolio manager
that have knowledge about the financing transaction contemplated by this Agreement. Moreover, notwithstanding the foregoing, in the event that a Purchaser has sold Securities pursuant to Rule 144 prior to the Effective Date of the initial
Registration Statement and the Company has failed to deliver certificates without legends prior to the settlement date for such sale (assuming that such certificates meet the requirements set forth in Section 4.1(c) for the
removal of legends), the provisions of this Section 4.12 shall not prohibit the Purchaser from entering into Net Short Sales for the purpose of delivering shares of Common Stock in settlement of such sale. Each Purchaser
understands and acknowledges, severally and not jointly with any other Purchaser, that the Commission currently takes the position that covering a short position established prior to effectiveness of a resale registration statement with shares
included in such registration statement would be a violation of Section 5 of the Securities Act, as set forth in Item 65, Section 5 under Section A, of the Manual of Publicly Available Telephone Interpretations, dated July 1997, compiled
by the Office of Chief Counsel, Division of Corporation Finance. 
 4.12 Beneficial Ownership Limitation. Notwithstanding anything to
the contrary set forth in the Series A Preferred Share Terms, the Company shall not effect any redesignation of the Series A Preferred Shares, and the Purchaser shall not have the right to redesignate any portion of its Series A Preferred Shares, to
the extent that, after giving effect to an attempted redesignation set forth on an applicable Notice of Conversion (as defined in the Series A Preferred Share Terms) with respect to the Series A Preferred Shares, such Purchaser (together with such
Purchaser’s Affiliates, and any other Person whose beneficial ownership of Common Stock would be aggregated with the Purchaser’s for purposes of Section 13(d) or Section 16 of the Exchange Act and the applicable rules and
regulations of the Commission, including any “group” of which the Purchaser is a member) would beneficially own a number of shares of Common Stock in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the
foregoing sentence, the aggregate number of shares of Common Stock beneficially owned by such Purchaser and its Affiliates shall include the number of shares of Common Stock created by the consolidation and redesignation of the Series A Preferred
Shares subject to the Notice of Conversion with respect to which the determination of such sentence is being made, but shall exclude the number of shares of Common Stock which are creatable or issuable upon (i) redesignation of the remaining,
unconverted Series A Preferred Shares beneficially owned by such Holder or any of its Affiliates, and (ii) exercise or conversion of the unexercised or unconverted portion of any other securities of the Company beneficially owned by such
Purchaser or any of its Affiliates (including, without limitation, any convertible notes, convertible stock or warrants) that are subject to a limitation on conversion or exercise analogous to the limitation contained herein. Except as set forth in
the preceding sentence, for purposes of this Section 4.12, beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the applicable rules and regulations of the Commission. In
addition, for purposes hereof, “group” has the meaning set forth in Section 13(d) of the Exchange Act and the applicable rules and regulations of the Commission. For purposes of this Section 4.12, in determining the number of
outstanding shares of Common Stock, a Purchaser may rely on the number of outstanding shares 

  
 24 













 
of Common Stock as reflected in (i) the Company’s most recent Form 10-K, Form 10-Q, Current Report on
Form 8-K or other public filing with the Commission, as the case may be, (ii) a more recent public announcement by the Company or (iii) a more recent notice by the Company setting forth the number of
shares of Common Stock then outstanding. For any reason at any time, upon the written or oral request of a Purchaser (which may be by email), the Company shall, within two (2) Business Days of such request, confirm orally and in writing to such
Purchaser (which may be by email) the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to any actual conversion or exercise of securities of the
Company, including Series A Preferred Shares, by such Purchaser or its Affiliates since the date as of which such number of outstanding shares of Common Stock was last publicly reported or confirmed to the Holder. The “Beneficial Ownership
Limitation” shall initially be 9.99% of the number of the shares of Common Stock outstanding immediately after giving effect to the creation or issuance of shares of Common Stock pursuant to such Notice of Conversion (to the extent permitted
pursuant to this Section 4.12). The Company shall be entitled to rely on representations made to it by the Purchaser in any Notice of Conversion regarding its Beneficial Ownership Limitation. By written notice to the
Company, a Purchaser may from time to time increase or decrease the Beneficial Ownership Limitation to any other percentage not in excess of 19.9% specified in such notice; provided that (i) any such increase will not be effective until the
sixty-first (61st) day after such notice is delivered to the Company. The provisions of this Section 4.12 shall be construed, corrected and implemented in a manner so as to effectuate the intended Beneficial Ownership
Limitation herein contained and the shares of Common Stock underlying the Securities in excess of the Beneficial Ownership Limitation shall not be deemed to be beneficially owned by the Purchaser for any purpose including for purposes of
Section 13(d) or Rule 16a-1(a)(1) of the Exchange Act. 
 4.13 Requisite Stockholder
Approval. The Company shall hold a special meeting of stockholders (a “Stockholder Meeting”) within 90 days from the Closing (the “Stockholder Meeting Deadline”) for the purpose of obtaining stockholder approval
of the conversion of all issued and outstanding Series A Preferred Stock into shares of Common Stock in accordance with the Nasdaq Stock Market Rules (the “Requisite Stockholder Approval”). The Company shall use its reasonable best
efforts to solicit its stockholders’ approval of such resolution and to cause the Board of Directors of the Company to recommend to the stockholders that they approve such resolution. If the Requisite Stockholder Approval is not obtained on or
prior to the Stockholder Meeting Deadline, the Company shall cause an additional Stockholder Meeting to be held within 90 days from the prior meeting (the “Extended Stockholder Approval Period”). If the Requisite Stockholder
Approval is not obtained within the Extended Stockholder Approval Period, then the Company shall convene additional stockholder meetings every 90 days thereafter until the Requisite Stockholder Approval is obtained. 

4.14 Conversion and Exercise Procedures. Each of the form of Notice of Conversion included in the Certificate of Designation set forth
the totality of the procedures required of the Purchasers in order to convert the Securities. Without limiting the preceding sentences, no ink-original Notice of Conversion shall be required, nor shall any
medallion guarantee (or other type of guarantee or notarization) of any Notice of Conversion form be required in order for the registered holder thereof to convert the Securities. No additional legal opinion, other information or instructions shall
be required of the Purchasers to convert their Securities. The Company shall honor conversions of the Securities and shall deliver Conversion Shares in accordance with the terms, conditions and time periods set forth in the Transaction Documents.


  
 25 













 ARTICLE V. 

CONDITIONS PRECEDENT TO CLOSING 

5.1 Conditions Precedent to the Obligations of the Purchasers to Purchase Securities. The obligation of each Purchaser to acquire
Securities at the Closing is subject to the fulfillment to such Purchaser’s satisfaction, on or prior to the Closing Date, of each of the following conditions, any of which may be waived by such Purchaser (as to itself only): 

(a) Representations and Warranties. The representations and warranties of the Company contained herein shall be true and correct in all
material respects (except for those representations and warranties which are qualified as to materiality, in which case such representations and warranties shall be true and correct in all respects) as of the date when made and as of the Closing
Date, as though made on and as of such date, except for such representations and warranties that speak as of a specific date. 
 (b)
Performance. The Company shall have performed, satisfied and complied in all material respects with all covenants, agreements and conditions required by the Transaction Documents to be performed, satisfied or complied with by it at or prior
to the Closing. 
 (c) No Injunction. No statute, rule, regulation, executive order, decree, ruling or injunction shall have been
enacted, entered, promulgated or endorsed by any court or Governmental Authority of competent jurisdiction that prohibits the consummation of any of the transactions contemplated by the Transaction Documents. 

(d) Consents. The Company shall have obtained in a timely fashion any and all consents, permits, approvals, registrations and waivers
necessary for consummation of the purchase and sale of the Securities (including all Required Approvals), all of which shall be and remain so long as necessary in full force and effect. 

(e) Adverse Changes. Since the date of execution of this Agreement, no event or series of events shall have occurred that has had or
would reasonably be expected to have a Material Adverse Effect. 
 (f) No Suspensions of Trading in Common Stock. The Common Stock
shall not have been suspended, as of the Closing Date, by the Commission or the Principal Trading Market from trading on the Principal Trading Market nor shall suspension by the Commission or the Principal Trading Market have been threatened, as of
the Closing Date, either (A) in writing by the Commission or the Principal Trading Market or (B) by falling below the minimum listing maintenance requirements of the Principal Trading Market. 

(g) Company Deliverables. The Company shall have delivered the Company Deliverables in accordance with
Section 2.2(a). 
 (h) Compliance Certificate. The Company shall have delivered to each Purchaser a
certificate, dated as of the Closing Date and signed by its Chief Executive Officer, its Chief Financial Officer or its Secretary, dated as of the Closing Date, certifying to the fulfillment of the conditions specified in Sections 5.1(a) and
(b) in the form attached hereto as Exhibit F. 
 (i) Merger. The Merger shall have been consummated in accordance
with the Merger Agreement. 

  
 26 













 (j) Termination. This Agreement shall not have been terminated as to such Purchaser
in accordance with Section 6.18 herein. 
 5.2 Conditions Precedent to the Obligations of the Company to issue
Securities. The Company’s obligation to issue the Securities at the Closing to the Purchasers is subject to the fulfillment to the satisfaction of the Company on or prior to the Closing Date of the following conditions, any of which may be
waived by the Company: 
 (a) Representations and Warranties. The representations and warranties made by the Purchasers in
Section 3.2 hereof shall be true and correct in all material respects (except for those representations and warranties which are qualified as to materiality, in which case such representations and warranties shall be true
and correct in all respects) as of the date when made, and as of the Closing Date as though made on and as of such date, except for representations and warranties that speak as of a specific date. 

(b) Performance. Such Purchaser shall have performed, satisfied and complied in all material respects with all covenants, agreements and
conditions required by the Transaction Documents to be performed, satisfied or complied with by such Purchaser at or prior to the Closing Date. 

(c) No Injunction. No statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered,
promulgated or endorsed by any court or Governmental Authority of competent jurisdiction that prohibits the consummation of any of the transactions contemplated by the Transaction Documents. 

(d) Purchasers Deliverables. Such Purchaser shall have delivered its Purchaser Deliverables in accordance with
Section 2.2(b). 
 (e) Merger. The Merger shall have been consummated in accordance with the Merger
Agreement. 
 (f) Termination. This Agreement shall not have been terminated as to such Purchaser in accordance with
Section 6.18 herein. 
 ARTICLE VI. 

MISCELLANEOUS 
 6.1 Fees and
Expenses. The Company and the Purchasers shall each pay the fees and expenses of their respective advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party in connection with the negotiation,
preparation, execution, delivery and performance of this Agreement. The Company shall pay all Transfer Agent fees, stamp taxes and other taxes and duties levied in connection with the sale and issuance and sale of the Securities to the Purchasers.

 6.2 Entire Agreement. The Transaction Documents, together with the exhibits and schedules thereto, contain the entire understanding
of the parties with respect to the subject matter hereof and supersede all prior agreements, understandings, discussions and representations, oral or written, with respect to such matters, which the parties acknowledge have been merged into such
documents, exhibits and schedules. At or after the Closing, and without further consideration, the Company and the Purchasers will execute and deliver to the other such further documents as may be reasonably requested in order to give practical
effect to the intention of the parties under the Transaction Documents. 

  
 27 













 6.3 Notices. Any and all notices or other communications or deliveries required or
permitted to be provided hereunder shall be in writing and shall be deemed given and effective on the earliest of (a) the date of transmission, if such notice or communication is delivered via electronic mail at the e-mail address specified in this Section 6.3 prior to 5:00 P.M., New York City time, on a Trading Day, (b) the next Trading Day after the date of transmission, if such notice or
communication is delivered via electronic mail at the e- mail address or facsimile number specified in this Section 6.3 on a day that is not a Trading Day or later than 5:00 P.M., New
York City time, on any Trading Day, (c) the Trading Day following the date of mailing, if sent by U.S. nationally recognized overnight courier service with next day delivery specified, or (d) upon actual receipt by the party to whom such
notice is required to be given. The address for such notices and communications shall be as follows: 
  

			
	If to the Company:	  	 Unum Therapeutics Inc.

 200 Cambridge Park
Drive, Suite 3100
Cambridge, Massachusetts

 Telephone No.: (617) 945-5576


Attention: Charles Wilson


E-mail: charles.wilson@unumrx.com

		
	With a copy to:	  	 Goodwin Procter LLP
 100 Northern Avenue

Boston, MA 02210
 Telephone No.: (617) 570-1000
 Attention: Danielle Lauzon

E-mail: DLauzon@goodwinlaw.com

		
	 If to a Purchaser:
	  	To the address set forth under such Purchaser’s name on the signature page hereof;

 or such other address as may be designated in writing hereafter, in the same manner, by such Person. 

6.4 Amendments; Waivers; No Additional Consideration. No provision of this Agreement may be waived, modified, supplemented or amended
except in a written instrument signed, in the case of an amendment, by the Company and the Purchasers of at least a majority in interest of the Securities still held by Purchasers or, in the case of a waiver, by the party against whom enforcement of
any such waiver is sought. No waiver of any default with respect to any provision, condition or requirement of this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other
provision, condition or requirement hereof, nor shall any delay or omission of either party to exercise any right hereunder in any manner impair the exercise of any such right. No consideration shall be offered or paid to any Purchaser to amend or
consent to a waiver or modification of any provision of any Transaction Document unless the same consideration is also offered to all Purchasers who then hold Securities. 

6.5 Construction. The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to
limit or affect any of the provisions hereof. The language used in this Agreement will be deemed to be the language chosen by the parties to express their mutual intent, and no rules of strict construction will be applied against any party. This
Agreement shall be construed as if drafted jointly by the parties, and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship of any provisions of this Agreement or any of the Transaction
Documents. 
 6.6 Successors and Assigns. The provisions of this Agreement shall inure to the benefit of and be binding upon the
parties and their successors and permitted assigns. This Agreement, or any rights or obligations hereunder, may not be assigned by the Company without the prior written consent of each Purchaser. Any Purchaser may assign its rights hereunder in
whole or in part to any Person to whom such Purchaser assigns or transfers any Securities in compliance with the Transaction Documents and applicable law, provided such transferee shall agree in writing to be bound, with respect to the transferred
Securities, by the terms and conditions of this Agreement that apply to the “Purchasers”. 

  
 28 













 6.7 No Third-Party Beneficiaries. This Agreement is intended for the benefit of the
parties hereto and their respective successors and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other Person, except the Placement Agent are an intended third party beneficiary of Article
III and Article IV hereof. 
 6.8 Governing Law. All questions concerning the construction, validity, enforcement
and interpretation of this Agreement shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of law thereof. Each party agrees that all Proceedings
concerning the interpretations, enforcement and defense of the transactions contemplated by this Agreement and any other Transaction Documents (whether brought against a party hereto or its respective Affiliates, employees or agents) shall be
commenced exclusively in the New York Courts. Each party hereto hereby irrevocably submits to the exclusive jurisdiction of the New York Courts for the adjudication of any dispute hereunder or in connection herewith or with any transaction
contemplated hereby or discussed herein (including with respect to the enforcement of any of the Transaction Documents), and hereby irrevocably waives, and agrees not to assert in any Proceeding, any claim that it is not personally subject to the
jurisdiction of any such New York Court, or that such Proceeding has been commenced in an improper or inconvenient forum. Each party hereto hereby irrevocably waives personal service of process and consents to process being served in any such
Proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good
and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law. EACH PARTY HERETO HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT
PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY. 

6.9 Survival. Subject to applicable statute of limitations, the representations, warranties, agreements and covenants contained herein
shall survive the Closing and the delivery of the Securities. 
 6.10 Execution. This Agreement may be executed in two or more
counterparts, all of which when taken together shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party, it being understood that both parties need
not sign the same counterpart. In the event that any signature is delivered by facsimile transmission, or by e- mail delivery of a “.pdf” format data file, such signature shall create a valid and
binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile signature page were an original thereof. 

6.11 Severability. If any provision of this Agreement is held to be invalid or unenforceable in any respect, the validity and
enforceability of the remaining terms and provisions of this Agreement shall not in any way be affected or impaired thereby and the parties will attempt to agree upon a valid and enforceable provision that is a reasonable substitute therefor, and
upon so agreeing, shall incorporate such substitute provision in this Agreement. 
 6.12 Rescission and Withdrawal Right.
Notwithstanding anything to the contrary contained in (and without limiting any similar provisions of) the Transaction Documents, whenever any Purchaser exercises a right, election, demand or option under a Transaction Document and the Company does
not timely perform its related obligations within the periods therein provided, then such Purchaser may rescind or withdraw, in its sole discretion from time to time upon written notice to the Company, any relevant notice, demand or election in
whole or in part without prejudice to its future actions and rights. 

  
 29 













 6.13 Replacement of Securities. If any certificate or instrument evidencing any
Securities or Conversion Shares is mutilated, lost, stolen or destroyed, the Company may issue or cause to be issued in exchange and substitution for and upon cancellation thereof, or in lieu of and substitution therefor, a new certificate or
instrument, but only upon receipt of evidence reasonably satisfactory to the Company and the Transfer Agent of such loss, theft or destruction and the execution by the holder thereof of a customary lost certificate affidavit of that fact and an
agreement to indemnify and hold harmless the Company and the Transfer Agent for any losses in connection therewith or, if required by the Transfer Agent, a bond in such form and amount as is required by the Transfer Agent. The applicants for a new
certificate or instrument under such circumstances shall also pay any reasonable third-party costs associated with the issuance of such replacement Securities or Conversion Shares. If a replacement certificate or instrument evidencing any Securities
or Conversion Shares is requested due to a mutilation thereof, the Company may require delivery of such mutilated certificate or instrument as a condition precedent to any issuance of a replacement. 

6.14 Remedies. In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of damages,
each of the Purchasers and the Company will be entitled to specific performance under the Transaction Documents. The parties agree that monetary damages may not be adequate compensation for any loss incurred by reason of any breach of obligations
described in the foregoing sentence and hereby agree to waive in any action for specific performance of any such obligation (other than in connection with any action for a temporary restraining order) the defense that a remedy at law would be
adequate. 
 6.15 Payment Set Aside. To the extent that the Company makes a payment or payments to any Purchaser pursuant to any
Transaction Document or a Purchaser enforces or exercises its rights thereunder, and such payment or payments or the proceeds of such enforcement or exercise or any part thereof are subsequently invalidated, declared to be fraudulent or
preferential, set aside, recovered from, disgorged by or are required to be refunded, repaid or otherwise restored to the Company, a trustee, receiver or any other person under any law (including, without limitation, any bankruptcy law, state or
federal law, common law or equitable cause of action), then to the extent of any such restoration the obligation or part thereof originally intended to be satisfied shall be revived and continued in full force and effect as if such payment had not
been made or such enforcement or setoff had not occurred. 
 6.16 Adjustments in Share Numbers and Prices. In the event of any stock
split, subdivision, dividend or distribution payable in shares of Common Stock (or other securities or rights convertible into, or entitling the holder thereof to receive directly or indirectly shares of Common Stock), combination or other similar
recapitalization or event occurring after the date hereof and prior to the Closing, each reference in any Transaction Document to a number of shares or a price per share shall be deemed to be amended to appropriately account for such event. 

6.17 Independent Nature of Purchasers’ Obligations and Rights. The obligations of each Purchaser under any Transaction Document are
several and not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the performance of the obligations of any other Purchaser under any Transaction Document. The decision of each Purchaser to
purchase Securities pursuant to the Transaction Documents has been made by such Purchaser independently of any other Purchaser and independently of any information, materials, statements or opinions as to the business, affairs, operations, assets,
properties, liabilities, results of operations, condition (financial or otherwise) or prospects of the Company or any Subsidiary which may have been made or given by any other Purchaser or by any agent or employee of any other Purchaser, and no
Purchaser and any of its agents or employees shall have any liability to any other Purchaser (or any other Person) relating to or arising from any such information, materials, statement or opinions. Nothing contained herein or in any Transaction
Document, and no action 

  
 30 













 
taken by any Purchaser pursuant thereto, shall be deemed to constitute the Purchasers as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that
the Purchasers are in any way acting in concert or as a group with respect to such obligations or the transactions contemplated by the Transaction Documents. Each Purchaser acknowledges that no other Purchaser has acted as agent for such Purchaser
in connection with making its investment hereunder and that no Purchaser will be acting as agent of such Purchaser in connection with monitoring its investment in the Securities or enforcing its rights under the Transaction Documents. Each Purchaser
shall be entitled to independently protect and enforce its rights, including without limitation the rights arising out of this Agreement or out of the other Transaction Documents, and it shall not be necessary for any other Purchaser to be joined as
an additional party in any proceeding for such purpose. Each Purchaser has been represented by its own separate legal counsel in its review and negotiation of the Transaction Documents. For reasons of administrative convenience only, Purchasers and
their respective counsels have chosen to communicate with the Company through Latham & Watkins LLP, counsel to the Placement Agent. Each Purchaser acknowledges that Latham & Watkins LLP has rendered legal advice to the Placement
Agents and not to such Purchaser in connection with the transactions contemplated hereby, and that each such Purchaser has relied for such matters on the advice of its own respective counsel. The Company has elected to provide all Purchasers with
the same terms and Transaction Documents for the convenience of the Company and not because it was required or requested to do so by any Purchaser. 

6.18 Termination. This Agreement may be terminated and the sale and purchase of the Securities abandoned at any time prior to the
Closing by either the Company or any Purchaser (with respect to itself only) upon written notice to the other, if the Closing has not been consummated on or prior to 5:00 P.M., New York City time, on the Outside Date; provided, however, that
the right to terminate this Agreement under this Section 6.18 shall not be available to any Person whose failure to comply with its obligations under this Agreement has been the cause of or resulted in the failure of the
Closing to occur on or before such time. Nothing in this Section 6.18 shall be deemed to release any party from any liability for any breach by such party of the terms and provisions of this Agreement or the other
Transaction Documents or to impair the right of any party to compel specific performance by any other party of its obligations under this Agreement or the other Transaction Documents. In the event of a termination pursuant to this
Section 6.18, the Company shall promptly notify all non-terminating Purchasers. Upon a termination in accordance with this Section 6.18, the Company and the
terminating Purchaser(s) shall not have any further obligation or liability (including arising from such termination) to the other, and no Purchaser will have any liability to any other Purchaser under the Transaction Documents as a result
therefrom. 
 6.19 Exculpation of the Placement Agents. Each party acknowledges that it has read the notice attached hereto as
Exhibit G and hereto agrees for the express benefit of the Placement Agent, its affiliates and its representatives that: 
 (a)
Neither the Placement Agent nor any of its affiliates or any of its representatives (1) has any duties or obligations other than those specifically set forth herein or in the engagement letter, dated as of July 2, 2020, between the Company and
Jefferies LLC (the “Engagement Letter”); (2) shall be liable for any improper payment made in accordance with the information provided by the Company; (3) makes any representation or warranty, or has any responsibilities as to the
validity, accuracy, value or genuineness of any information, certificates or documentation delivered by or on behalf of the Company pursuant to this Agreement or the Transaction Documents or in connection with any of the transactions contemplated
hereby and thereby; or (4) shall be liable (x) for any action taken, suffered or omitted by any of them in good faith and reasonably believed to be authorized or within the discretion or rights or powers conferred upon it by this Agreement
or any Transaction Document or (y) for anything which any of them may do or refrain from doing in connection with this Agreement or any Transaction Document, except for such party’s own gross negligence or willful misconduct. 

  
 31 













 (b) The Placement Agent, its affiliates and its representatives shall be entitled to
(1) rely on, and shall be protected in acting upon, any certificate, instrument, notice, letter or any other document or security delivered to it by or on behalf of the Company, including the representations made by the Company and the
Investors herein, and (2) be indemnified by the Company for acting as the Placement Agent hereunder pursuant the indemnification provisions set forth in the Engagement Letter. 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 

  
 32 













 IN WITNESS WHEREOF, the parties hereto have caused this Securities Purchase Agreement to be
duly executed by their respective authorized signatories as of the date first indicated above. 
  

			
	UNUM THERAPEUTICS INC.
		
	By:	 	 /s/ Charles Wilson, Ph.D.

		 	Name: Charles Wilson, Ph.D.
		 	Title: President and Chief Executive Officer


 [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 












 
			
	NAME OF PURCHASER: [***]
		
	By:	 	 

     

	Name: 
	Title: 
	
	Aggregate Series A Preferred Shares Purchase Price (Preferred Subscription Amount): $1,000,000
	
	Number of Series A Preferred Shares to be Acquired: 1,136
	
	Tax ID No.:
                                    
	
	Address for Notice:
	  

	  

	  

	
	Telephone No.:
                                    
	
	Facsimile No.:
                                    
	
	E-mail Address:
                                    
	
	Attention:
                                    


 Delivery Instructions: 

(if different than above) 
 c/o
                                         
            
 Street:
                                         
     
 City/State/Zip:
                                 

Attention:
                                        

 Telephone No.:
                                         
    












 
			
	NAME OF PURCHASER: Fairmount Healthcare Fund LP
		
	By:	 	 /s/ Peter Harwin

	Name: Peter Harwin
	Title: Managing Member
	
	Aggregate Series A Preferred Shares Purchase Price (Preferred Subscription Amount): $3,249,393.00
	
	Number of Series A Preferred Shares to be Acquired: 3,692
	
	Tax ID
No.:                                    
	
	Address for Notice:
	
	  

	  

	  

	
	Telephone No.:
                                    
	
	Facsimile No.:
                                    
	
	E-mail Address:
                                    
	
	Attention:
                                    


  

	
	Delivery Instructions:
	(if different than above)
	
	c/o
                                         
               
	
	Street:
                                         
           
	
	City/State/Zip:
                                        

	
	Attention:
                                         
       
	
	Telephone No.:
                                         
           













 
			
	NAME OF PURCHASER: Fairmount Healthcare Fund II LP
		
	By:	 	 /s/ Peter Harwin

	Name: Peter Harwin
	Title: Managing Member
	
	Aggregate Series A Preferred Shares Purchase Price (Preferred Subscription Amount): $16,750,607.00
	Number of Series A Preferred Shares to be Acquired: 19,035
	
	Tax ID No.:
                                    
	
	Address for Notice:
	
	  

	  

	  

	
	Telephone No.:
                                    
	
	Facsimile No.:
                                      
	
	E-mail Address:
                                    
	
	Attention:
                                    


  

	
	Delivery Instructions:
	(if different than above)
	
	c/o
                                         
                
	
	Street:
                                         
           
	
	City/State/Zip:
                                        

	
	Attention:
                                         
       
	
	Telephone No.:
                                         
           













 
			
	NAME OF PURCHASER: Orbimed Partners Master Fund Limited
		
	By:	 	 /s/ Geoffrey Hsu

	Name: Geoffrey Hsu
	Title: Member
	
	Aggregate Series A Preferred Shares Purchase Price (Preferred Subscription Amount): $5,000,000.00
	
	Number of Series A Preferred Shares to be Acquired: 5,682
	
	Tax ID No.:
                                     
	
	Address for Notice:
	  

	  

	  

	
	Telephone No.:
                                     
	
	Facsimile No.:
                                      
	
	E-mail Address:
                                    
	
	Attention:
                                    


  

	
	Delivery Instructions:
	(if different than above)
	
	c/o
                                         
                
	
	Street:
                                         
           
	
	City/State/Zip:
                                        

	
	Attention:
                                         
       
	
	Telephone No.:
                                         
           













 
			
	NAME OF PURCHASER: Orbimed Genesis Master Fund, L.P.
		
	By:	 	 /s/ Geoffrey Hsu

	Name: Geoffrey Hsu
	Title: Member
	
	Aggregate Series A Preferred Shares Purchase Price (Preferred Subscription Amount): $2,000,000.00
	
	 Number of Series A Preferred Shares to be Acquired:

2,273

	
	Tax ID No.:
                                    
	
	Address for Notice:
	
	  

	  

	  

	
	Telephone No.:
                                     
	
	Facsimile No.:
                                      
	
	E-mail Address:
                                    
	
	Attention:
                                    


  

	
	Delivery Instructions:
	(if different than above)
	
	c/o
                                         
               
	
	Street:
                                         
           
	
	City/State/Zip:
                                        

	
	Attention:
                                         
       
	
	Telephone No.:
                                         
           













 
			
	NAME OF PURCHASER: Ally Bridge MedAlpha Master Fund L.P.
		
	By:	 	 /s/ Fan YU

	Name: Fan YU
	Title: Manager of Ally Bridge MedAlpha GP LLC acting as General Partner of Ally Bridge MedAlpa General Partner L.P. acting as General Partner of Ally Bridge MedAlpha Master Fund L.P.
	
	Aggregate Series A Preferred Shares Purchase Price (Preferred Subscription Amount): $5,000,000.00
	
	Number of Series A Preferred Shares to be Acquired: 5,682
	
	Tax ID No.:
                                      
	
	Address for Notice:
	
	  

	  

	  

	
	Telephone No.:
                                    
	
	Facsimile No.:
                                     
	
	E-mail Address:
                                    
	
	Attention:
                                    


  

	
	Delivery Instructions:
	(if different than above)
	
	c/o
                                         
               
	
	Street:
                                         
           
	
	City/State/Zip:
                                        

	
	Attention:
                                         
       
	
	Telephone No.:
                                         
           













 
			
	NAME OF PURCHASER: RTW Innovation Master Fund, Ltd.
		
	By:	 	 /s/ Roderick Wong

	Name: Roderick Wong
	Title: Director
	
	Aggregate Series A Preferred Shares Purchase Price (Preferred Subscription Amount): $1,887,340.00
	
	Number of Series A Preferred Shares to be Acquired: 2,145
	
	Tax ID No.:
                                    
	
	Address for Notice:
	
	  

	  

	  

	
	Telephone No.:
                                     
	
	Facsimile No.:
                                      
	
	E-mail Address:
                                    
	
	Attention:
                                    


 Delivery Instructions: 

(if different than above) 
 c/o
                                        
                 
 Street:
                                        
             
 City/State/Zip:
                                        
 
 Attention:
                                        
         
 Telephone No.:
                                        
             












 
			
	NAME OF PURCHASER: RTW Venture Fund Limited
		
	By:	 	 /s/ Roderick Wong

	Name: Roderick Wong
	Title: Managing Partner of the Investment Manager
	
	Aggregate Series A Preferred Shares Purchase Price (Preferred Subscription Amount): $197,750.00
	
	Number of Series A Preferred Shares to be Acquired: 225
	
	Tax ID No.:
	
	Address for Notice:
	  

	  

	  

	
	Telephone
No.:                                    
	
	Facsimile
No.:                                    
	
	E-mail
Address:                                    
	
	Attention:                                  
  


 Delivery Instructions: 

(if different than above) 
 c/o
                                        
             
 Street:
                                        
      
 City/State/Zip:
                                 

Attention:
                                        
 
 Telephone No.:
                                        
     












 
			
	NAME OF PURCHASER: RTW Master Fund Limited
		
	By:	 	 /s/ Roderick Wong

	Name: Roderick Wong
	Title: Director
	
	Aggregate Series A Preferred Shares Purchase Price (Preferred Subscription Amount): $7,000,000.00
	
	 Number of Series A Preferred Shares to be Acquired:

7,955

	
	Tax ID No.:
	
	Address for Notice:
	  

	  

	  

	
	Telephone
No.:                                    
	
	Facsimile
No.:                                    
	
	E-mail
Address:                                    
	
	Attention:                                  
  


 Delivery Instructions: 

(if different than above) 
 c/o
                                        
             
 Street:
                                        
      
 City/State/Zip:
                                 

Attention:
                                        
 
 Telephone No.:
                                         
    












 
			
	NAME OF PURCHASER: Acorn Bioventures, L.P.
	
	By: Acorn Capital Advisors GP, LLC, its general partner
		
	By:	 	 /s/ Isaac Manke             

	Name: Isaac Manke
	Title: Member
	
	Aggregate Series A Preferred Shares Purchase Price (Preferred Subscription Amount): $10,000,000.00
	
	Number of Series A Preferred Shares to be Acquired: 11,364
	
	Tax ID No.:
	
	Address for Notice:
	  

	  

	  

	
	Telephone
No.:                                    
	
	Facsimile
No.:                                    
	
	E-mail
Address:                                    
	
	Attention:                                  
  


 Delivery Instructions: 

(if different than above) 
 c/o
                                         
            
 Street:
                                         
     
 City/State/Zip:
                                 

Attention:
                                        

 Telephone No.:
                                         
    












 
			
	NAME OF PURCHASER: Venrock Healthcare Capital Partners III, L.P.
	
	By: VHCP Management III, LLC, its general partner
		
	By:	 	 /s/ David L. Stepp            

	Name: David L. Stepp
	Title: Authorized Signatory
	
	Aggregate Series A Preferred Shares Purchase Price (Preferred Subscription Amount): $6,858,000.00
	
	Number of Series A Preferred Shares to be Acquired: 7,793
	
	Tax ID No.:
	
	Address for Notice:
	  

	  

	  

	
	Telephone No.:
                                    
	
	Facsimile No.:
                                    
	
	E-mail Address:
                                    
	
	Attention:
                                    


 Delivery Instructions: 

(if different than above) 
 c/o
                                         
            
 Street:
                                         
     
 City/State/Zip:
                                 

Attention:
                                        

 Telephone No.:
                                         
    












 
			
	NAME OF PURCHASER: VHCP Co-Investment Holdings III, LLC
	
	By: VHCP Management III, LLC, its manager
		
	By:	 	 /s/ David L. Stepp            

	Name: David L. Stepp
	Title: Authorized Signatory
	
	Aggregate Series A Preferred Shares Purchase Price (Preferred Subscription Amount): $685,200.00
	
	Number of Series A Preferred Shares to be Acquired: 779
	
	Tax ID No.:
	
	Address for Notice:
	  

	  

	  

	
	Telephone
No.:                                    
	
	Facsimile
No.:                                    
	
	E-mail
Address:                                    
	
	Attention:                                  
  


 Delivery Instructions: 

(if different than above) 
 c/o
                                         
            
 Street:
                                         
     
 City/State/Zip:
                                 

Attention:
                                        

 Telephone No.:
                                         
    












 
			
	NAME OF PURCHASER: Biotechnology Value Fund, L.P.
		
	By:	 	 /s/ Mark Lampert        

	Name: Mark Lampert
	Title: Chief Executive Officer BVF I GP LLC, itself General Partner of Biotechnology Value Fund, L.P.
	
	Aggregate Series A Preferred Shares Purchase Price (Preferred Subscription Amount): $5,222,800.00
	
	Number of Series A Preferred Shares to be Acquired: 5935
	
	Tax ID No.:
                                    
	
	Address for Notice:
	  

	  

	  

	
	Telephone No.:
                                    
	
	Facsimile No.:
                                    
	
	E-mail Address:
                                    
	
	Attention:
                                    


 Delivery Instructions: 

(if different than above) 
 c/o
                                         
            
 Street:
                                         
     
 City/State/Zip:
                                 

Attention:
                                        

 Telephone No.:
                                         
    












 
			
	NAME OF PURCHASER: Biotechnology Value Fund II, L.P.
		
	By:	 	 /s/ Mark
Lampert                    

	Name: Mark Lampert
	Title: Chief Executive Officer BVF II GP LLC, itself General Partner of Biotechnology Value Fund II, L.P.
	
	Aggregate Series A Preferred Shares Purchase Price (Preferred Subscription Amount): $3,895,760.00
	
	Number of Series A Preferred Shares to be Acquired: 4,427
	
	Tax ID No.:
                                    
	
	Address for Notice:
	  

	  

	  

	
	Telephone No.:
                                    
	
	Facsimile No.:
                                    
	
	E-mail Address:
                                    
	
	Attention:
                                    


 Delivery Instructions: 

(if different than above) 
 c/o
                                         
            
 Street:
                                         
     
 City/State/Zip:
                                 

Attention:
                                        

 Telephone No.:
                                         
    












 
			
	NAME OF PURCHASER: Biotechnology Value Trading Fund OS, L.P.
		
	By:	 	 /s/ Mark
Lampert                    

	Name: Mark Lampert
	Title: President BVF Inc., General Partner of BVF Partners L.P., itself sole member of BVF Partners OS Ltd., itself GP of Biotechnology Value Trading Fund OS, L.P.
	
	Aggregate Series A Preferred Shares Purchase Price (Preferred Subscription Amount): $679,360
	
	Number of Series A Preferred Shares to be Acquired: 772
	
	Tax ID No.:
                                    
	
	Address for Notice:
	  

	  

	  

	
	Telephone No.:
                                    
	
	Facsimile No.:
                                    
	
	E-mail Address:
                                    
	
	Attention:
                                    


 Delivery Instructions: 

(if different than above) 
 c/o
                                         
            
 Street:
                                         
     
 City/State/Zip:
                                 

Attention:
                                        

 Telephone No.:
                                         
    












 
			
	NAME OF PURCHASER: MSI BVF SPC L.L.C.
		
	By:	 	 /s/ Mark
Lampert                    

	Name: Mark Lampert
	Title: President BVF Inc., General Partner of BVF Partners L.P., itself attorney-in-fact for MSI BVF SPV, L.L.C.
	
	Aggregate Series A Preferred Shares Purchase Price (Preferred Subscription Amount): $201,520.00
	
	Number of Series A Preferred Shares to be Acquired: 229
	
	Tax ID No.:
                                    
	
	Address for Notice:
	  

	  

	  

	
	Telephone No.:
                                    
	
	Facsimile No.:
                                    
	
	E-mail Address:
                                    
	
	Attention:
                                    


 Delivery Instructions: 

(if different than above) 
 c/o
                                         
            
 Street:
                                         
     
 City/State/Zip:
                                 

Attention:
                                        

 Telephone No.:
                                         
    












 
			
	 NAME OF PURCHASER: Logos Opportunities Fund II, L.P.
  

By: Logos Opportunities GP, LLC, its General Partner

		
	By:	 	 /s/Graham Walmsley            

	Name: Graham Walmsley
	Title: Manager
	
	Aggregate Series A Preferred Shares Purchase Price (Preferred Subscription Amount): $5,000,000.00
	
	Number of Series A Preferred Shares to be Acquired: 5,682
	
	Tax ID No.:
                                    
	
	Address for Notice:
	  

	  

	  

	
	Telephone No.:
                                    
	
	Facsimile No.:
                                    
	
	E-mail Address:
                                    
	
	Attention:
                                    


 Delivery Instructions: 

(if different than above) 
 c/o
                                         
            
 Street:
                                         
     
 City/State/Zip:
                                 

Attention:
                                        

 Telephone No.:
                                         
    












 
			
	NAME OF PURCHASER: VHCP CO-INVESTMENT HOLDINGS II, LLC
	
	By: VHCP Management II, LLC, its manager
		
	By:	 	 /s/ David L. Stepp

	Name: David L. Stepp
	Title: Authorized Signatory
	
	Aggregate Series A Preferred Shares Purchase Price (Preferred Subscription Amount): $ 1,285,200.00
	
	Number of Series A Preferred Shares to be Acquired: 1,460
	
	Tax ID No.:
	
	Address for Notice:
	  

	  

	  

	
	Telephone No.:
                                    
	
	Facsimile No.:
                                    
	
	E-mail Address:
                                    
	
	Attention:
                                    


 Delivery Instructions: 

(if different than above) 
 c/o
                                         
            
 Street:
                                         
     
 City/State/Zip:
                                 

Attention:
                                        

 Telephone No.:
                                         
    












 
			
	NAME OF PURCHASER: Atlas Venture Fund XI, L.P.
	
	 By: Atlas Venture Associates XI, L.P., its GP

By: Atlas Venture Associates XI, LLC, its GP

		
	By:	 	 /s/ Ommer Chohan

	Name: Ommer Chohan
	Title: CFO
	
	Aggregate Series A Preferred Shares Purchase Price (Preferred Subscription Amount): $10,000,000.00
	
	Number of Series A Preferred Shares to be Acquired: 11,364
	
	Tax ID No.:
	
	Address for Notice:
	  

	  

	  

	
	Telephone No.:
                                    
	
	Facsimile No.:
                                    
	
	E-mail Address:
                                    
	
	Attention:
                                    


 Delivery Instructions: 

(if different than above) 
 c/o
                                         
            
 Street:
                                         
     
 City/State/Zip:
                                 

Attention:
                                        

 Telephone No.:
                                         
    












 
			
	NAME OF PURCHASER: Commodore Capital Master LP
		
	By:	 	 /s/ Michael Kramarz, MD

	Name: Michael Kramarz, MD
	Title: Authorized Signatory
	
	Aggregate Series A Preferred Shares Purchase Price (Preferred Subscription Amount): $_2,250,000.00
	
	Number of Series A Preferred Shares to be Acquired: 2,557
	
	Tax ID No.:
	
	Address for Notice:
	  

	  

	  

	
	Telephone No.:
                                    
	
	Facsimile No.:
                                    
	
	E-mail Address:
                                    
	
	Attention:
                                    


 Delivery Instructions: 

(if different than above) 
 c/o
                                         
            
 Street:
                                         
     
 City/State/Zip:
                                 

Attention:
                                        

 Telephone No.:
                                         
    












 
			
	NAME OF PURCHASER: [***]
		
	By:	 	      

	Name: 
	Title: 
	
	Aggregate Series A Preferred Shares Purchase Price (Preferred Subscription Amount): $150,000.00
	
	Number of Series A Preferred Shares to be Acquired: 170
	
	Tax ID No.:
	
	Address for Notice:
	  

	  

	  

	
	Telephone No.:
                                    
	
	Facsimile No.:
                                    
	
	E-mail Address:
                                    
	
	Attention:
                                    


 Delivery Instructions: 

(if different than above) 
 c/o
                                         
            
 Street:
                                         
     
 City/State/Zip:
                                 

Attention:
                                        

 Telephone No.:
                                         
    












 
			
	NAME OF PURCHASER: Samsara BioCapital, L.P.
	
	By: Samsara BioCapital GP, LLC, its General Partner
		
	By:	 	 /s/ Srinivas Akkaraju, MD, PhD

	Name: Srinivas Akkaraju, MD, PhD
	Title: Managing General Partner
	
	Aggregate Series A Preferred Shares Purchase Price (Preferred Subscription Amount): $5,000,000.00
	
	Number of Series A Preferred Shares to be Acquired: 5,682
	
	Tax ID No.:
	
	Address for Notice:
	  

	  

	  

	
	Telephone No.:
                                    
	
	Facsimile No.:
                                    
	
	E-mail Address:
                                    
	
	Attention:
                                    


 Delivery Instructions: 

(if different than above) 
 c/o
                                         
            
 Street:
                                         
     
 City/State/Zip:
                                 

Attention:
                                        

 Telephone No.:
                                         
    












 
			
	NAME OF PURCHASER: [***]
		
	By:	 	      

	Name: 
	Title: 
	
	Aggregate Series A Preferred Shares Purchase Price (Preferred Subscription Amount): $3,000,000.00
	
	Number of Series A Preferred Shares to be Acquired: 3,409
	
	Tax ID No.:
	
	Address for Notice:
	  

	  

	  

	
	Telephone No.:
                                    
	
	Facsimile No.:
                                    
	
	E-mail Address:
                                    
	
	Attention:
                                    


 Delivery Instructions: 

(if different than above) 
 c/o
                                         
            
 Street:
                                         
     
 City/State/Zip:
                                 

Attention:
                                        

 Telephone No.:
                                         
    












 
			
	NAME OF PURCHASER: Perceptive Life Sciences Master Fund, Ltd.
		
	By:	 	 /s/ James H. Mannix

	Name: James H. Mannix
	Title: Chief Operating Officer
	
	Aggregate Series A Preferred Shares Purchase Price (Preferred Subscription Amount): $7,000,000.00
	
	Number of Series A Preferred Shares to be Acquired: 7,955
	
	Tax ID No.:
	
	Address for Notice:
	  

	  

	  

	
	Telephone No.:
                                    
	
	Facsimile No.:
                                    
	
	E-mail Address:
                                    
	
	Attention:
                                    


 Delivery Instructions: 

(if different than above) 
 c/o
                                         
            
 Street:
                                         
     
 City/State/Zip:
                                 

Attention:
                                        

 Telephone No.:
                                         
    












 
			
	NAME OF PURCHASER: Venrock Healthcare Capital Partners II, L.P.
	
	 By: VHCP Management II, LLC, its general partner

		
	By:	 	 /s/ David L. Stepp

	Name: David L. Stepp
	Title: Authorized Signatory
	
	Aggregate Series A Preferred Shares Purchase Price (Preferred Subscription Amount): $3,171,600.00
	
	Number of Series A Preferred Shares to be Acquired: 3,604
	
	Tax ID No.:
	
	Address for Notice:
	  

	  

	  

	
	Telephone No.:
                                    
	
	Facsimile No.:
                                    
	
	E-mail Address:
                                    
	
	Attention:
                                    


 Delivery Instructions: 

(if different than above) 
 c/o
                                         
            
 Street:
                                         
     
 City/State/Zip:
                                 

Attention:
                                        

 Telephone No.:
                                         
    












 Annex A: Schedule of Purchasers 

EXHIBITS: 
  

	A:	 Certificate of Designations 



 

	B:	 Form of Registration Rights Agreement 



 

	C:	 Share Certificate Questionnaire 



 

	D:	 Form of Irrevocable Transfer Agent Instructions 



 

	E:	 Form of Secretary’s Certificate 



 

	F:	 Form of Officers’ Certificate 



 

	G:	 Jefferies Required Disclosure 



 

	H:	 Merger Agreement 














 SCHEDULE OF PURCHASERS 

[***] 












 EXHIBIT A 

CERTIFICATE OF DESIGNATIONS 












 EXHIBIT B 

FORM OF REGISTRATION RIGHTS AGREEMENT 












 EXHIBIT C 

STOCK CERTIFICATE QUESTIONNAIRE 

Pursuant to Section 2.2(b) of the Agreement, please provide us with the following information: 

 

					
	1.	  	The exact name that the Securities are to be registered in (this is the name that will appear on the stock certificate(s)). You may use a nominee name if appropriate:	  	  

			
	2.	  	The relationship between the Purchaser of the Securities and the Registered Holder listed in response to Item 1 above:	  	  

			
	3.	  	The mailing address, telephone and telecopy number of the Registered Holder listed in response to Item 1 above:	  	  

		
		  	  

		
		  	  

		
		  	  

		
		  	  

			
	4.	  	The U.S. Tax Identification Number (or, if an individual, the U.S. Social Security Number) of the Registered Holder listed in response to Item 1 above:	  	  














 EXHIBIT D 

FORM OF IRREVOCABLE TRANSFER AGENT INSTRUCTIONS 

As of                 ,
         
 [Insert Name of Transfer Agent] 

[Address] 
 [Address] 

Attn:
                                 

Ladies and Gentlemen: 
 Reference
is made to that certain Securities Purchase Agreement, dated as of , 2020 (the “Agreement”), by and among Unum Therapeutics Inc., a Delaware corporation (the “Company”), and the purchasers named on the
signature pages thereto (collectively, and including permitted transferees, the “Holders”), pursuant to which the Company is issuing to the Holders shares (the “Shares”) of Series A
Non- Voting Convertible Preferred Stock, par value $0.001 per share (the “Series A Preferred Stock”), which will be convertible into shares (the “Conversion Shares”) of the
Company’s common stock, par value $0.001 per share (the “Common Stock”). 
 This letter shall serve as our irrevocable
authorization and direction to you (provided that you are the transfer agent of the Company at such time and the conditions set forth in this letter are satisfied), subject to any stop transfer instructions that we may issue to you from time to
time, if any, to issue shares of Common Stock upon the conversion of the Series A Preferred Stock to or upon the order of a Holder from time to time upon delivery of an executed Notice of Effectiveness of Registration Statement, in the form attached
hereto as Annex I. 
 You acknowledge and agree that so long as you have received (a) written confirmation from the Company’s legal
counsel that either (1) a registration statement covering resales of the Shares has been declared effective by the Securities and Exchange Commission (the “Commission”) under the Securities Act of 1933, as amended (the
“Securities Act”), or (2) the Shares have been sold in conformity with Rule 144 under the Securities Act (“Rule 144”) or are eligible for sale under Rule 144, without the requirement for the Company to be in
compliance with the current public information required under Rule 144 as to such securities and without volume or manner-of-sale restrictions and (b) if
applicable, a copy of such registration statement, then, unless otherwise required by law, within three (3) Trading Days of your receipt of a notice of transfer or Shares, you shall issue the certificates representing the Shares registered in
the names of such Holders or transferees, as the case may be, and such certificates shall not bear any legend restricting transfer of the Shares thereby and should not be subject to any stop-transfer restriction; provided, however, that if
such Shares are not registered for resale under the Securities Act or able to be sold under Rule 144 without the requirement for the Company to be in compliance with the current public information required under Rule 144 as to such securities and
without volume or manner-of-sale restrictions, then the certificates for such Shares shall bear the following legend: 

 

					
		  	THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED
(I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OR (B) AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT	  	














					
		  	AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS OR BLUE SKY LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE COMPANY AND ITS TRANSFER AGENT OR (II) UNLESS SOLD PURSUANT TO RULE 144 UNDER
THE SECURITIES ACT. NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES.	  	

 A form of written confirmation from the Company’s outside legal counsel that a registration statement
covering resales of the Shares has been declared effective by the Commission under the Securities Act is attached hereto as Annex I. 

Please be advised that the Holders are relying upon this letter as an inducement to enter into the Agreement and, accordingly, each Holder is
a third party beneficiary to these instructions. 
 Please execute this letter in the space indicated to acknowledge your agreement to act
in accordance with these instructions. 
  

			
	Very truly yours,


 
			
	
	[INSERT NAME OF COMPANY]


 
			
		
	By:	 	  



 
			
	Name:	 	  



 
			
	Title:	 	  




 

			
	Acknowledged and Agreed:


			
	
	[INSERT NAME OF TRANSFER AGENT]


			
		
	By:	 	  



			
	Name:	 	  



			
	Title:	 	  



			
	Date:                         ,
        













 Annex I 

FORM OF NOTICE OF EFFECTIVENESS OF REGISTRATION STATEMENT 
  

	
	 [Insert Name of Transfer Agent]
 [Address]

[Address]

Attn:                        



 Re: [Insert Name of Company] 

Ladies and Gentlemen: 
 We are counsel to Unum
Therapeutics Inc., a Delaware corporation (the “Company”), and have represented the Company in connection with that certain Securities Purchase Agreement, dated as of _______ , ___ , entered into by and among the Company and the
purchasers named therein (collectively, the “Purchasers”) pursuant to which the Company issued to the Purchasers shares of the Company’s Series A Non-Voting Convertible Preferred Stock,
$0.001 par value per share (the “Shares”). Pursuant to that certain Registration Rights Agreement of even date, the Company agreed to register the resale of the Shares (collectively, the “Registrable Securities”),
under the Securities Act of 1933, as amended (the “Securities Act”). In connection with the Company’s obligations under the Registration Rights Agreement,
                 on,         , the Company filed a Registration Statement on Form S-3 (File No. 333-            ) (the “Registration Statement”) with the Securities and Exchange Commission (the
“Commission”) relating to the Registrable Securities which names each of the Purchasers as a selling stockholder thereunder. 

In connection with the foregoing, we advise you that a member of the Commission’s staff has advised us by telephone that the Commission
has entered an order declaring the Registration Statement effective under the Securities Act at                  [a.m.][p.m.] on _______ ,
___ , and we have no knowledge, after reviewing the Commission’s “Stop Orders” web page (http://sec.gov/litigation/stoporders.shtml), that any stop order suspending its effectiveness has been issued or that any proceedings for that
purpose are pending before, or threatened by, the Commission and the Registrable Securities are available for resale under the Securities Act pursuant to the Registration Statement. 

This letter shall serve as our standing notice to you that the Shares may be freely transferred by the Purchasers pursuant to the Registration
Statement. You need not require further letters from us to effect any future legend-free issuance or reissuance of shares of Common Stock to the Purchasers or the transferees of the Purchasers, as the case may be, as contemplated by the
Company’s Irrevocable Transfer Agent Instructions dated                 ,        , provided at the time of
such reissuance, the Company has not otherwise notified you that the Registration Statement is unavailable for the resale of the Registrable Securities. This letter shall serve as our standing instructions with regard to this matter. 

 

			
	Very truly yours,
	
	[INSERT NAME OF COMPANY COUNSEL]


 
			
		
	By:	 	  















 EXHIBIT E 

FORM OF SECRETARY’S CERTIFICATE 
 The
undersigned hereby certifies that Erin Schellhammer is the duly elected, qualified and acting Secretary of Unum Therapeutics Inc., a Delaware corporation (the “Company”), and that as such he is authorized to execute and deliver this
certificate in the name and on behalf of the Company and in connection with the Securities Purchase Agreement, dated as of                  ,
         , by and among the Company and the investors party thereto (the “Securities Purchase Agreement”), and further certifies in his official capacity, in the name and on behalf of the
Company, the items set forth below. Capitalized terms used but not otherwise defined herein shall have the meaning set forth in the Securities Purchase Agreement. 
  

	1.	 Attached hereto as Exhibit A is a true, correct and complete copy of the resolutions duly adopted by the
Board of Directors of the Company at a meeting held on                  . Such resolutions have not in any way been amended, modified, revoked or rescinded, have
been in full force and effect since their adoption to and including the date hereof and are now in full force and effect. 


  

	2.	 Attached hereto as Exhibit B is a true, correct and complete copy of the Certificate of Incorporation of
the Company, together with any and all amendments thereto currently in effect, and no action has been taken to further amend, modify or repeal such Certificate of Incorporation, the same being in full force and effect in the attached form as of the
date hereof 


  

	3.	 Attached hereto as Exhibit C is a true, correct and complete copy of the Bylaws of the Company and any and all
amendments thereto currently in effect, and no action has been taken to further amend, modify or repeal such Bylaws, the same being in full force and effect in the attached form as of the date hereof. 



 

	4.	 Each person listed below has been duly elected or appointed to the position(s) indicated opposite his name and
is duly authorized to sign the Securities Purchase Agreement and each of the Transaction Documents on behalf of the Company, and the signature appearing opposite such person’s name below is such person’s genuine signature.



  

					
	 Name
	  	 Position
	  	 Signature

	Charles Wilson	  	Chief Executive Officer	  	  

			
	John Green	  	Chief Financial Officer	  	  



 IN WITNESS WHEREOF, the undersigned has hereunto set his hand as of
this                 day of                 ,
    . 
  

	
	  

	Secretary














 I, Charles Wilson, Ph.D., Chief Executive Officer, hereby certify that Erin Schellhammer is the duly
elected, qualified and acting Secretary of the Company and that the signature set forth above is his true signature. 
  

	
	  

	Chief Executive Officer














 EXHIBIT A 

Resolutions 












 EXHIBIT B 

Certificate of Incorporation 












 EXHIBIT C 

Bylaws 












 EXHIBIT F 

FORM OF OFFICER’S CERTIFICATE 
 The
undersigned, the Chief Executive Officer and Chief Financial Officer of Unum Therapeutics Inc., a Delaware corporation (the “Company”), pursuant to Section 5.1(i) of the Securities Purchase Agreement, dated as
of                        , by and among the Company and the investors signatory thereto (the “Securities Purchase
Agreement”), hereby represents, warrants and certifies as follows (capitalized terms used but not otherwise defined herein shall have the meaning set forth in the Securities Purchase Agreement): 

 

	 	1.	 The representations and warranties of the Company contained in the Securities Purchase Agreement are true and
correct in all material respects (except for those representations and warranties which are qualified as to materiality, in which case, such representations and warranties shall be true and correct in all respects) as of the date when made and as of
the date hereof, as though made on and as of such date, except for such representations and warranties that speak as of a specific date. 


  

	 	2.	 The Company has performed, satisfied and complied in all material respects with all covenants, agreements and
conditions required by the Transaction Documents to be performed, satisfied or complied with by it at or prior to the date hereof. 


 IN
WITNESS WHEREOF, the undersigned has executed this certificate this          day of
                        ,             . 

 

	
	  

	Chief Executive Officer
	  

	Chief Financial Officer














 EXHIBIT G 

Jefferies Required Disclosure 
 On
February 2, 2016, pursuant to an offer of settlement by Jefferies LLC, the SEC entered an administrative order, pursuant to its Municipalities Continuing Disclosure Cooperation (“MCDC”) initiative, finding that Jefferies LLC, in
connection with its underwriting of certain municipal securities offerings, willfully violated Section 17(a)(2) of the Securities Act of 1933. The administrative order requires Jefferies LLC to cease and desist from committing or causing any
violations or any future violations of Section 17(a)(2), to pay a civil penalty, and to complete certain undertakings. Jefferies LLC received waivers from the SEC of any disqualifications under Regulations A (Rule 262), D (Rule 505 and 506),
and E arising from the settlement, effective as of February 2, 2016. The SEC Order is available at https://www.sec.gov/rules/other/2016/33-10030.pdf. 












 EXHIBIT H 

Merger Agreement